预约演示
更新于：2026-01-24
Tesidolumab
更新于：2026-01-24
概要
基本信息
原研机构 |
在研机构- |
权益机构- |
最高研发阶段终止临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 148002H
来源: *****
Sequence Code 148008L
来源: *****
关联
9
项与 Tesidolumab 相关的临床试验NCT02878616
Open-label, Parallel-group, Drug-drug Interaction Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316
Investigate whether concomitant treatment with intravenous immunoglobulin (IVIG) can alter the pharmacokinetics and pharmacodynamics of LFG316 to an extent which would necessitate dose adaptation for LFG316 in pre-sensitized end-stage renal disease patients awaiting kidney transplantation
开始日期2016-08-26 |
NCT02763644
A Randomized, Open Label, Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LFG316 in Patients With Transplant Associated Microangiopathy After Hematopoietic Precursor Cell Transplantation
This was a randomized, SoC-controlled, open-label, multi-center study in patients with TAM after hematopoietic precursor cell transplantation (HPCT) .
Study consisted of up to 28 days of screening period, 16 weeks treatment period that can be extended to 45 weeks.Approximately 40 patients was to be randomized to receive SoC or LFG316 plus SoC. Patients was included in the study if they have diagnosis of TAM and poor prognostic markers. This trial was terminated: LFG316, a monoclonal antibody inhibitor of complement factor 5 (C5), had been studied in seven patients with transplantation-associated microangiopathy (TAM). Due to low confidence of clinical benefit, this study was closed
Study consisted of up to 28 days of screening period, 16 weeks treatment period that can be extended to 45 weeks.Approximately 40 patients was to be randomized to receive SoC or LFG316 plus SoC. Patients was included in the study if they have diagnosis of TAM and poor prognostic markers. This trial was terminated: LFG316, a monoclonal antibody inhibitor of complement factor 5 (C5), had been studied in seven patients with transplantation-associated microangiopathy (TAM). Due to low confidence of clinical benefit, this study was closed
开始日期2016-04-22 |
NCT02515942
A Randomized, Multi-Center, Single Masked, Sham Controlled, Proof-of-Concept Study of Intravitreal CLG561 as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy
The purpose of this study is to evaluate the safety and efficacy of 12 (every 28 days) intravitreal (IVT) injections of CLG561 as a monotherapy and in combination with LFG316 as compared to sham in subjects with geographic atrophy.
开始日期2015-09-25 |
申办/合作机构 Alcon Research Ltd. [+1] |
100 项与 Tesidolumab 相关的临床结果
登录后查看更多信息
100 项与 Tesidolumab 相关的转化医学
登录后查看更多信息
100 项与 Tesidolumab 相关的专利（医药）
登录后查看更多信息
6
项与 Tesidolumab 相关的文献（医药）2024-07-01·XENOTRANSPLANTATION
Iscalimab Combined With Transient Tesidolumab Prolongs Survival in Pig‐to‐Rhesus Monkey Renal Xenografts
Article
作者: Matar, Abraham J. ; Adams, Andrew B. ; Faber, David ; Burlak, Christopher ; Tector, Alfred J. ; Lovasik, Brendan P. ; Tector, Matt ; Kim, Steven C.
ABSTRACT:
Objective:
To evaluate the clinically relevant anti‐CD40 antibody iscalimab for baseline immunosuppression in a preclinical pig‐to‐rhesus renal xenograft model.
Summary Background Data:
CD40/CD40L co‐stimulation blockade‐based immunosuppression has been more successful than calcineurin‐based protocols in prolonging xenograft survival in preclinical models.
Methods:
GGTA1 knockout/CD55 transgenic pig kidneys were transplanted into rhesus monkeys (n = 6) receiving an iscalimab‐based immunosuppressive regimen.
Results:
Two grafts were lost early (22 and 26 days) because of ectatic donor ureters with otherwise normal histology. The other recipients survived 171, 315, 422, and 439 days with good renal function throughout the posttransplant course. None of the recipients experienced serious infectious morbidity.
Conclusions:
It may be reasonable to evaluate an iscalimab‐based immunosuppressive regimen in clinical renal xenotransplantation.
2024-05-01·International journal of laboratory hematology
Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy
Review
作者: Fattizzo, Bruno ; Versino, Francesco
Abstract:
Complement inhibitors are the mainstay of paroxysmal nocturnal hemoglobinuria (PNH) treatment. The anti‐C5 monoclonal antibody eculizumab was the first treatment to improve hemolysis, thrombotic risk, and survival in PNH although at the price of a life‐long intravenous fortnightly drug. Additionally, suboptimal response may occur in up to 2/3 of patients with persistent anemia due to incomplete control of intravascular hemolysis, development of upstream C3‐mediated extravascular hemolysis (EVH), or concomitant bone marrow failure. Ravulizumab, a longer half‐life anti‐C5 developed from eculizumab, administered every 8 weeks, improved patient convenience, and reduced pharmacokinetic breakthrough hemolysis (BTH) by establishing more stable anti‐C5 concentrations. More recently, several other anti‐C5 compounds (crovalimab, pozelimab, tesidolumab, cemdisiran, zilucoplan, and coversin) are on study in clinical trials. Upstream inhibition of complement cascade was also explored with the anti‐C3 pegcetacoplan, and with the alternative pathway inhibitors iptacopan (anti‐factor B) and danicopan (anti‐factor D). These drugs efficiently target EVH and are able to improve anemia and transfusion need in suboptimal responders to anti‐C5. The route and schedule of administration (twice weekly subcutaneously for pegcetacoplan and twice or thrice oral daily dosing for iptacopan and danicopan, respectively) are very convenient but pose novel issues regarding adherence. Additionally, both anti‐C5 and upstream inhibitors do not resolve the unmet need of pharmacodynamic BTH events due to complement amplifying conditions such as infections, traumas, and surgery. In this review, we will recapitulate PNH physiopathology, clinical presentation, and diagnosis and describe available and developing drugs that will lead to a precision medicine approach for this rare though heterogenous disease.
2022-06-06·Polish Archives of Internal Medicine-Polskie Archiwum Medycyny Wewnetrznej
Paroxysmal nocturnal hemoglobinuria: advances in the understanding of pathophysiology, diagnosis, and treatment
Review
作者: Szlendak, Urszula ; Budziszewska, Bożena ; Drozd-Sokołowska, Joanna ; Spychalska, Justyna ; Patkowska, Elżbieta ; Nowak, Jacek
In recent years, "old" paroxysmal nocturnal hemoglobinuria (PNH) has achieved new advances in terms of the understanding of its pathophysiology, modern approach to diagnostics, optimization of therapy, and dynamic development of new therapeutic agents. This review emphasizes the greater than previously recognized importance of the reduced susceptibility of PNH stem cells to apoptosis in the selection of a defective clone. Some changes in cytokine and chemokine profiles in patients with PNH have been interpreted in the context of autoimmunity and apoptosis. The classification of PNH presentations, characteristics of the functions of selected glycosylphosphatidylinositol-anchored proteins, as well as pathologies associated with hemolysis, thrombosis, and bone marrow failure are described. The current diagnostic process for various forms of PNH is presented in detail, as well as its importance in the choice of treatment and prognosis of the disease course. Determinants of modern treatment, such as strategies (complement C5 inhibitors vs hematopoietic stem cell allotransplantation), the safety and efficacy of treatment with eculizumab or ravulizumab, policy of initiation and monitoring of treatment, the criteria for response to treatment and final outcomes of treatment are described. Among the new therapeutic agents, crovalimab and C5 inhibitors at a less advanced stage of research are discussed: tesidolumab, pozelimab, zilucoplan, nomacopan, and cemdisiran. The first approved proximal complement pathway inhibitors that primarily prevent extravascular hemolysis, pegcetacoplan, danikopan, and iptacopan, are presented and their potential benefits are highlighted.
57
项与 Tesidolumab 相关的新闻（医药）2025-12-31
·肤界
2025年，国际皮肤科领域持续快速发展。越来越多来自中国的研究者，出现在 British Journal of Dermatology（BJD）、Journal of the American Academy of Dermatology（JAAD）、JAMA Dermatology、
Journal of the European Academy Of Dermatology and Venereology（JEADV）、Journal Investigative of Dermatology（JID）、Nature、Cell等国际权威期刊的作者名单中。这些论文是中国皮肤科在全球学术舞台上持续发声、深入对话的成果。
延续上篇盘点，肤界编辑部继续整理2025年度来自中国作者的研究成果，涵盖皮肤科不同方向与创新前沿。这份盘点记录了中国皮肤科的年度精彩成果，每一篇上榜论文，都是2025年中国皮肤科研路上的闪亮印记。
这是你2025年的一部分
也是中国皮肤科这一年共同完成的一次亮相
这一页，值得被留在2025年末的朋友圈里
2025年度JAMA Dermatology合集列表
（最新IF：11.0）
1.经皮耳迷走神经刺激治疗红斑毛细血管扩张性玫瑰痤疮：一项随机临床试验
Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Erythematotelangiectatic Rosacea: A Randomized Clinical Trial
Jian Li 1, Jinyu Wei 2, Mingwang Zhang, Minmin Kong, Lijuan Xie, Mei Wan, Zhifei Pan, Jing Tian, Zuzhen Ou, Shuguang Chen, Aiai Xia, Li Tang, Zhiqiang Song, Jingming Hou, Fei Hao
JAMA Dermatol. 2025 Dec 1;161(12):1229-1237.
PMID: 41060641
PMCID: PMC12509084 (available on 2026-10-08)
DOI: 10.1001/jamadermatol.2025.3796
2.伊马替尼治疗胃肠道间质瘤期间广泛性瘢痕疙瘩的消退
Regression of Extensive Keloids During Imatinib Therapy for Gastrointestinal Stromal Tumor
Yi-Han Chang 1, John A McGrath 1, Chao-Kai Hsu
JAMA Dermatol. 2025 Dec 1;161(12):1293-1294.
PMID: 41191377 DOI: 10.1001/jamadermatol.2025.4072
3.颈部环形皮肤病变
Annular Cutaneous Lesion of the Neck
Yi-Xiao Wang 1, Min Gao 1, Li-Xiong Gu
JAMA Dermatol. 2025 Nov 1;161(11):1177-1178.
PMID: 40991266 DOI: 10.1001/jamadermatol.2025.2592
4.乌帕替尼治疗汗孔角化症
Treatment of Porokeratosis Ptychotropica With Upadacitinib
Shuai Zhang, Lu Bian, Meng-Yao Zhang, Jin-Fa Dou, Hong-Wei Liu, Jian-Guo Li, Jian-Bo Wang
JAMA Dermatol. 2025 Nov 1;161(11):1191-1193.
PMID: 41032324 DOI: 10.1001/jamadermatol.2025.3519
5.银屑病治疗中的生物制剂转换：系统评价与荟萃分析
Biopharmaceutical Switching in Psoriasis Treatment: A Systematic Review and Meta-Analysis
Miao Zhang, Seokgyeong Hong, Qingyun Wang, Xiaoying Sun, Yaqiong Zhou, Ying Luo, Liu Liu , Jiao Wang, Chunxiao Wang, Naixuan Lin, Juntang Yan, Xin Li
JAMA Dermatol. 2025 Aug 6;161(10):1029-1038.
PMID: 40768223
PMCID: PMC12329682 (available on 2026-08-06)
DOI: 10.1001/jamadermatol.2025.2714
6.2-光子显微镜对黄褐斑病理特征及治疗反应的体内评估
In Vivo Evaluation of Melasma Pathologic Features and Treatment Response by 2-Photon Microscopy
Xiaoli Ning, Jungang Yang, Hongfei Ouyang, Lingfan Jiang, Ruixing Yu, Chengxu Li, Yujun Sheng, Xuejiao Song, Jingkai Xu, Xianbo Zuo, Yong Cui
JAMA Dermatol. 2025 Aug 13;161(10):1039-1047.
PMID: 40802269
PMCID: PMC12351471 (available on 2026-08-13)
DOI: 10.1001/jamadermatol.2025.2790
7.用于皮肤海分支杆菌感染病因学诊断的靶向新一代测序
Targeted Next-Generation Sequencing for Etiologic Diagnosis of Cutaneous Mycobacterium marinum Infection
An-Kang Gu, Wen-Hua Qin, Xiu-Jun Zhang, Fa-Ku Ma, Li-Tao Zhang
JAMA Dermatol. 2025 Aug 20;161(10):1086-1087.
PMID: 40833738
PMCID: PMC12368782 (available on 2026-08-20)
DOI: 10.1001/jamadermatol.2025.2905
8.增生性扁平苔藓
Hypertrophic Lichen Planus
Ruimiao Wu, Yu Hu
JAMA Dermatol. 2025 Sep 3.
PMID: 40900583 DOI: 10.1001/jamadermatol.2025.2995
9.埃万妥单抗诱导的头皮及面部坏死局部β阻滞剂湿敷疗法
Topical β-Blocker Wet Wrap Therapy for Amivantamab-Induced Scalp and Facial Necrosis
Hsuan-Chi Chen, Wen-Hung Chung 1, How-Wen Ko 2, Jong-Hwei Su Pang 4, Yu-Shien Ko, Mei-Jun Chen, Chun-Wei Lu
JAMA Dermatol. 2025 Sep 10.
PMID: 40928786 DOI: 10.1001/jamadermatol.2025.3122
10.寻常型狼疮
Lupus Vulgaris
Chuan-Peng Wang, Jia Zhou, Jun Li
JAMA Dermatol. 2025 Sep 1;161(9):970-971.
PMID: 40668574 DOI: 10.1001/jamadermatol.2025.1799
11.伴淋巴管炎的先天性耳聋
Orf With Lymphangitis
Yi-Shan Teng, Ting-Ting Yang
JAMA Dermatol. 2025 Sep 1;161(9):972-973.
PMID: 40768138 DOI: 10.1001/jamadermatol.2025.2400
12.乌帕替尼用于治疗高IgE综合征
Upadacitinib for Treatment of Hyper-IgE Syndrome
Qing Zhao 1, Yanhong Sun 1, Yonghu Sun 1, Hong Liu 1, Furen Zhang
JAMA Dermatol. 2025 Sep 1;161(9):984-985.
PMID: 40768139 DOI: 10.1001/jamadermatol.2025.2699
13.林普利塞联合西达本胺在复发或难治性皮肤T细胞淋巴瘤中的应用：一项非随机临床试验
Linperlisib Plus Chidamide in Relapsed or Refractory Cutaneous T-Cell Lymphoma: A Nonrandomized Clinical Trial
Zhiyu Pang, Yupeng Wang 2, Zhaorui Liu, Shan Zhang, Chong Wei, Zhuofan Xu, Ziqian Wang, Hongyun Chen, Jie Liu, Wei Zhang
JAMA Dermatol. 2025 Sep 1;161(9):923-930.
PMID: 40601335
PMCID: PMC12224036 (available on 2026-07-02)
DOI: 10.1001/jamadermatol.2025.1926
14.接受度普利尤单抗治疗的特应性皮炎患者中的银屑病风险
Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab
Teng-Li Lin 1, Yi-Hsuan Fan, Kuo-Sheng Fan, Chao-Kuei Juan, Yi-Ju Chen, Chun-Ying Wu
JAMA Dermatol. 2025 Aug 1;161(8):813-821.
PMID: 40531497
PMCID: PMC12177727 (available on 2026-06-18)
DOI: 10.1001/jamadermatol.2025.1578
15.癌症患者抗肿瘤治疗后的自身免疫性皮肤病与生存结局
Autoimmune Skin Diseases and Survival Outcomes After Antineoplastic Treatment in Patients With Cancer
Sheng-Yin To 1, Cho-Hao Lee, Yi-Hsien Chen 6, Li-Fan Hsu, I-Wen Chen 3, Hui-Wen Yang, Yuan-Liang Wen, Li-Ting Kao
JAMA Dermatol. 2025 Aug 1;161(8):840-848.
PMID: 40601336
PMCID: PMC12224047 (available on 2026-07-02)
DOI: 10.1001/jamadermatol.2025.1949
16.下肢无症状对称性毛细血管扩张症
Asymptomatic Symmetrical Telangiectasia on Lower Extremities
Pei-Yun Ho, Yi-Tsz Lin
JAMA Dermatol. 2025 Aug 1;161(8):874-875.
PMID: 40531494 DOI: 10.1001/jamadermatol.2025.1416
17.儿童嗜酸性粒细胞增多伴全身症状的药物反应
Drug Reaction With Eosinophilia and Systemic Symptoms in Children
Lei Jiao, Yang Wang, Jing Tian, Mutong Zhao, Zigang Xu, Lin Ma, Yuan Liang
JAMA Dermatol. 2025 Aug 1;161(8):881-883.
PMID: 40531516
PMCID: PMC12177722 (available on 2026-06-18)
DOI: 10.1001/jamadermatol.2025.1651
18.与绑蟹相关的孢子丝菌病暴发
An Outbreak of Sporotrichosis Associated With Tying Crabs
Fangfang Bao, Pengcheng Huai, Chenchen Chen, Shufen Wang, Yong Zhang, Zige Li, Yongxia Liu, Gongqi Yu, Wenyan Ma, Meichen Han, Wenchang Zhao, Hong Liu 1, Furen Zhang
JAMA Dermatol. 2025 Aug 1;161(8):883-885.
PMID: 40601347
PMCID: PMC12224045 (available on 2026-07-02)
DOI: 10.1001/jamadermatol.2025.1884
19.司库奇尤单抗与乌帕替尼治疗Papillon-Lefèvre综合征2例报告
Secukinumab and Upadacitinib Treatment for Papillon-Lefèvre Syndrome in 2 Cases
Jiaying Li 1, Zhaoyang Wang 1, Zigang Xu
JAMA Dermatol. 2025 Aug 1;161(8):887-890.
PMID: 40632515 DOI: 10.1001/jamadermatol.2025.1639
20.1990年至2021年老年人皮肤癌负担及2050年模型预测
Burden of Skin Cancer in Older Adults From 1990 to 2021 and Modelled Projection to 2050
Ruiyao Wang, Yangmei Chen, Xinyi Shao, Tingqiao Chen, Judan Zhong, Yi Ou, Jin Chen
JAMA Dermatol. 2025 Jul 1;161(7):715-722.
PMID: 40397469
PMCID: PMC12096324
DOI: 10.1001/jamadermatol.2025.1276
21.Hutchinson-Gilford早衰综合征
Hutchinson-Gilford Progeria Syndrome
Yu-Ting Tsai, Yi-Chien Yang
JAMA Dermatol. 2025 Jul 1;161(7):755-756.
PMID: 40366683 DOI: 10.1001/jamadermatol.2025.0793
22.艾玛昔替尼治疗成人及青少年中重度特应性皮炎：一项3期随机临床试验
Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents: A Phase 3 Randomized Clinical Trial
Yan Zhao, Melinda Gooderham, Bin Yang, Jiyuan Wu, Liming Wu, Wei Jing Loo, Darryl Toth, Maxwell Sauder, Jingyi Li, Aijun Chen, Xiaohua Tao, Jianyun Lu, Zhiqiang Song, Jiande Han, Hongyi Li, Yijing Li, Lihong Xu, Jianzhong Zhang
JAMA Dermatol. 2025 Jul 1;161(7):688-697.
PMID: 40305055
PMCID: PMC12044538 (available on 2026-04-30)
DOI: 10.1001/jamadermatol.2025.0982
23.外阴和大腿上的丘疹性及水疱性皮损
Papular and Vesicular Lesions on the Vulva and Thighs
Teng Liu, Jianmin Chang
JAMA Dermatol. 2025 Jul 1;161(7):761-762.
PMID: 40465257 DOI: 10.1001/jamadermatol.2025.1407
24.具有新型MGP变异的弹性假黄瘤样表型
Pseudoxanthoma Elasticum-Like Phenotype With a Novel MGP Variant
Yun-Shiuan Olivia Hsu, Rai-Hseng Hsu, Jau-Yu Liau, Ni-Chung Lee, Yin-Hsiu Chien, Yi-Hua Liao
JAMA Dermatol. 2025 Jul 1;161(7):773-775.
PMID: 40397434 DOI: 10.1001/jamadermatol.2025.1019
25.TRPM4基因合子后获得性功能增强变异与炎症性线状疣状表皮痣
Postzygotic Gain-of-Function Variant in TRPM4 and Inflammatory Linear Verrucous Epidermal Nevus
Zhouliang Liu, Zhijun Zhao, Kunlun Lv, Huijun Wang, Fan Yang, Zhimiao Lin
JAMA Dermatol. 2025 Jul 23.
PMID: 40699612 DOI: 10.1001/jamadermatol.2025.2205
26.阿布昔替尼治疗滑膜炎、痤疮、脓疱病、增生症及骨炎综合征
Treatment of Synovitis, Acne, Pustulosis, Hyperstosis, and Osteitis Syndrome With Abrocitinib
Dawei Huang 1, Yujing Zhao 2, Yuling Shi 1, Xuemei Yi
JAMA Dermatol. 2025 Jun 1;161(6):668-669.
PMID: 40332901 DOI: 10.1001/jamadermatol.2025.1010
27.前胸孤立性红斑
An Isolated Red Plaque on the Anterior Chest
Bin Peng, Xiaojuan Nan, Songmei Geng
JAMA Dermatol. 2025 Jun 1;161(6):652-653.
PMID: 40305037 DOI: 10.1001/jamadermatol.2025.0745
28.单纯光动力疗法与抗生素联合治疗皮肤马立克氏菌感染
Cutaneous Mycobacterium marinum Treated With Photodynamic Therapy Alone and Combined With Antibiotics
Wenlong Hu, Qiunan Yao, Yue Mou, Chaochao Ji, Wenhao Cheng, Renqiong Chen, Jiaqi Liu, Xudong Mou, Di Cao, Hong Ren
JAMA Dermatol. 2025 Jun 1;161(6):663-666.
PMID: 40266582
PMCID: PMC12019672 (available on 2026-04-23)
DOI: 10.1001/jamadermatol.2025.0645
29.脱毛性毛囊炎
Folliculitis Decalvans
Lijuan Zhou, Jinran Lin, Wenyu Wu
JAMA Dermatol. 2025 May 1;161(5):544-545.
PMID: 40105835 DOI: 10.1001/jamadermatol.2025.0050
30.妊娠期化脓性汗腺炎用药影响的再评估
Reexamining Medication Impact in Hidradenitis Suppurativa and Pregnancy
Yan-Han Li, Shu-Han Chuang, Hui-Ju Yang
JAMA Dermatol. 2025 May 1;161(5):561.
PMID: 40202763 DOI: 10.1001/jamadermatol.2025.0507
31.甲下无色素性黑色素瘤
Subungual Amelanotic Melanoma
Xing Fang, Tianjing Gao, Yu Fu
JAMA Dermatol. 2025 Apr 1;161(4):432-433.
PMID: 40042859 DOI: 10.1001/jamadermatol.2024.6167
32.发热性溃疡坏死性Mucha-Habermann病
Febrile Ulceronecrotic Mucha-Habermann Disease
Yi-Hsuan Shen, Yu-Ting Hung
JAMA Dermatol. 2025 Apr 1;161(4):430-431.
PMID: 39969860 DOI: 10.1001/jamadermatol.2024.6162
33. Stevens-Johnson综合征/中毒性表皮坏死松解症幸存者心血管疾病发病率与死亡率风险
Risk of Cardiovascular Morbidity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Survivors
Hsien-Yi Chiu, Ying-Ming Chiu
JAMA Dermatol. 2025 Apr 1;161(4):391-398.
PMID: 39969876
PMCID: PMC11840681 (available on 2026-02-19)
DOI: 10.1001/jamadermatol.2024.5881
34.胸部圆形坏死性黄红色斑块
Circular Necrotic Yellow-Red Plaque on the Chest
Tian-Yi Zhang 1, Yue-Ping Zeng
JAMA Dermatol. 2025 Apr 1;161(4):434-435.
PMID: 40042862 DOI: 10.1001/jamadermatol.2025.0028
35.贫血痣
Nevus Anemicus
Xuemei Lan, Xiaopo Wang
JAMA Dermatol. 2025 Mar 1;161(3):322-323.
PMID: 39937468 DOI: 10.1001/jamadermatol.2024.6031
36.抗IL-23单克隆抗体QX004N治疗银屑病的安全性与有效性：一项随机临床试验
Safety and Efficacy of Anti-IL-23 Monoclonal Antibody QX004N for Patients With Psoriasis: A Randomized Clinical Trial
Xiaojiao Li, Bing Li, Deming Yang, Meng Wang, Qianqian Li, Nan Wang, Min Fang, Jingrui Liu, Hong Zhang, Min Wu, Cuiyun Li, Xiaoxue Zhu, Yanhua Ding, Shanshan Li
JAMA Dermatol. 2025 Mar 1;161(3):247-255.
PMID: 39661362
PMCID: PMC11840649
DOI: 10.1001/jamadermatol.2024.5059
37.年轻女性肉芽肿性唇炎
Granulomatous Cheilitis in a Young Woman
Zheng Su, Si-Jia Zhao, Yue-Ping Zeng
JAMA Dermatol. 2025 Feb 1;161(2):210-211.
PMID: 39745741 DOI: 10.1001/jamadermatol.2024.5502
38.免疫检查点抑制剂与银屑病风险
Psoriasis Risk With Immune Checkpoint Inhibitors
Sheng-Yin To, Cho-Hao Lee, Yi-Hsien Chen, Chia-Lu Hsu, Hui-Wen Yang, Ying-Shan Jiang, Yuan-Liang Wen, I-Wen Chen 3, Li-Ting Kao
JAMA Dermatol. 2025 Jan 1;161(1):31-38.
PMID: 39504056
PMCID: PMC11541743
DOI: 10.1001/jamadermatol.2024.4129
39.手掌筋膜炎和多关节炎综合征
Palmar Fasciitis and Polyarthritis Syndrome
Xiao Ma, Dong-Lai Ma
JAMA Dermatol. 2025 Jan 1;161(1):98-99.
PMID: 39630476 DOI: 10.1001/jamadermatol.2024.5015
40.佩索利单抗在糖皮质激素抵抗性Sweet综合征患者中的疗效
Spesolimab Response in a Patient With Steroid-Resistant Sweet Syndrome
Zhiyu Pang, Chao Wu, Jie Liu, Yuehua Liu, Hongzhong Jin
JAMA Dermatol. 2025 Jan 1;161(1):110-112.
PMID: 39535809 DOI: 10.1001/jamadermatol.2024.4342
2025年度JEADV合集列表
（最新IF：8.0）
1.利特昔替尼治疗斑秃的真实世界疗效与安全性：单中心经验
Real-world efficacy and safety of ritlecitinib in alopecia areata: A single-centre experience
Youyu Sheng , Qin Wang , Ke Tao , Kai Yang , Yifei Zhu , Zheng Li , Chunya Ni , Jinran Lin , Wenyu Wu
J Eur Acad Dermatol Venereol. 2025 Dec;39(12):e996-e998.
PMID: 40130934 DOI: 10.1111/jdv.20664
2.对Preuß 等人‘度普利尤单抗：倾向性匹配队列中未发现母体风险升高’的回应
Response to 'Dupilumab: No elevated maternal risks in propensity-matched cohort' by Preuß et al
Yan Teng , Qiong Gao , Jie Chen , Xiaohua Tao
J Eur Acad Dermatol Venereol. 2025 Dec;39(12):e1079-e1080.
PMID: 40616363 DOI: 10.1111/jdv.20819
3.度普利尤单抗降低特应性皮炎感染风险的获益尚未得到充分认识
Underrecognized infection-reducing benefits of dupilumab in atopic dermatitis
Shiuan-Chih Chen, Yuan-Ti Lee
J Eur Acad Dermatol Venereol. 2025 Dec;39(12):e1063-e1064.
PMID: 40536414 DOI: 10.1111/jdv.20805
4.AI生成皮肤科图像中的隐藏模式与被忽视的陷阱：超越表面多样性
Hidden patterns and overlooked pitfalls in AI-generated dermatology images: Beyond surface diversity
Chao-Bin Yeh , Shiuan-Chih Chen
J Eur Acad Dermatol Venereol. 2025 Dec;39(12):e1065-e1066.
PMID: 40785165 DOI: 10.1111/jdv.70002
5.以急性乳腺炎为首发表现的二期梅毒
Secondary syphilis with acute mastitis as the initial manifestation
Ming-Ming Zhou, Long Geng
J Eur Acad Dermatol Venereol. 2025 Dec;39(12):2142.
PMID: 40052240 DOI: 10.1111/jdv.20592
6.婴儿血管瘤对普萘洛尔治疗反应不佳的危险因素：一项前瞻性研究
Risk factors for a poor response to propranolol for infantile haemangioma: A prospective study
Kaizhi Zhang , Tong Qiu , Xue Gong , Jiangyuan Zhou , Yuru Lan , Zixin Zhang , Yi Ji
J Eur Acad Dermatol Venereol. 2025 Dec;39(12):e1039-e1041.
PMID: 40624963 DOI: 10.1111/jdv.20840
7.瘢痕疙瘩与增生性瘢痕病灶内治疗的疼痛模式：一项多中心观察性研究
Pain patterns in intralesional therapy for keloids and hypertrophic scars: A multicenter observational study
Yunyi Liu, Zixi Jiang, Dan Sun, Liang Zhang, Renliang He, Shuang Zhao
J Eur Acad Dermatol Venereol. 2025 Nov;39(11):e979-e982.
PMID: 40459278 DOI: 10.1111/jdv.20758
8.用于手术台针具管理的粘性磁性托盘
An adhesive magnetic tray for on-surgical-table needle management
Guoqun Yu , Fan Yang , Liu Yang , Yamin Zhang , Juan Tao
J Eur Acad Dermatol Venereol. 2025 Nov;39(11):e977-e978.
PMID: 40365773 DOI: 10.1111/jdv.20749
9.高频超声检查联合Mohs显微手术治疗复发性 DFSP
High-frequency ultrasonography combined with Mohs micrographic surgery for treating recurrent DFSP
Yuancheng Liu, Shuang Zhao, Tianhong Wei
J Eur Acad Dermatol Venereol. 2025 Nov;39(11):e983-e986.
PMID: 40298455 DOI: 10.1111/jdv.20722
10.平衡疗效与患者体验：模拟日光PDT治疗浅表BCC的审慎视角
Balancing efficacy and patients experience: A cautious perspective on simulated daylight PDT for superficial BCC
Davis Yung Chan , Raphael Chan
J Eur Acad Dermatol Venereol. 2025 Nov;39(11):1876-1877.
PMID: 41137684 DOI: 10.1111/jdv.70018
11.牧民Orf病毒感染：一种模拟猴痘病毒（Mpox）及其他皮肤病变的人畜共患病毒
Orf virus infection in a herder: A zoonotic poxvirus mimicking Mpox and other cutaneous lesions
Xu Li, Qiri Mu
J Eur Acad Dermatol Venereol. 2025 Nov;39(11):2005.
PMID: 40231386 DOI: 10.1111/jdv.20695
12.JAK抑制剂治疗扁平苔藓性脱发或额部纤维性脱发的疗效与安全性
Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
Chaofan Wang , Yiqun Jiang
J Eur Acad Dermatol Venereol. 2025 Oct;39(10):e882-e885.
PMID: 39995396 DOI: 10.1111/jdv.20614
13.全身性神经激肽-1受体拮抗剂缓解慢性瘙痒：系统评价与荟萃分析
Systemic neurokinin-1 receptor antagonists mitigate chronic pruritus: A systematic review and meta-analysis
Pei-Yun Ho , Yu-Chen Huang, Yi-Tsz Lin
J Eur Acad Dermatol Venereol. 2025 Oct;39(10):1738-1749.
PMID: 40551532 DOI: 10.1111/jdv.20807
14.口服乌帕替尼联合窄谱中波紫外线治疗难治性进展性白癜风的病例系列研究
Treatment of refractory progressive vitiligo with oral upadacitinib and narrow-band ultraviolet-B: A case series
Zhenhua Yue, Xiaoxiao Yan, Yonghu Sun
J Eur Acad Dermatol Venereol. 2025 Oct;39(10):e854-e856.
PMID: 39902936 DOI: 10.1111/jdv.20565
15.紫外线诱导荧光皮肤镜在斑秃毛囊开口检测中的应用
Ultraviolet-induced fluorescence dermoscopy in detecting follicular openings in alopecia areata
Xiaofan Jin , Wen Xu , Yujie Li , Xiuzu Song
J Eur Acad Dermatol Venereol. 2025 Oct;39(10):e860-e861.
PMID: 39898616 DOI: 10.1111/jdv.20576
16.时机、年龄与免疫特征分析优化地衣样慢性移植物抗宿主病治疗策略
Timing, age and immune profiling refine strategy in lichenoid chronic graft-versus-host disease
Shiuan-Chih Chen, Tsai Ling Ting
J Eur Acad Dermatol Venereol. 2025 Oct;39(10):e934-e935.
PMID: 40600498 DOI: 10.1111/jdv.20823
17.对Kakpovbia关于轻中度痤疮局部治疗有效性的文章评论
Comment on the article by Kakpovbia about efficacy of topical treatments for mild-to-moderate acne
Qing Long , Yan Li
J Eur Acad Dermatol Venereol. 2025 Oct;39(10):e940-e941.
PMID: 40536411 DOI: 10.1111/jdv.20800
18.对Kogler关于生殖道外性传播感染流行率文章的评论
Comment on the article by Kogler about prevalence of extragenital sexually transmitted infections
Yan Li , Qing Long
J Eur Acad Dermatol Venereol. 2025 Oct;39(10):e942-e943.
PMID: 40552892 DOI: 10.1111/jdv.20804
19.评估异维A酸妊娠预防依从性时未解决的混杂因素：呼吁进行更精细的分析
Unaddressed confounders in the evaluation of isotretinoin pregnancy prevention compliance: A call for refined analyses
Jianjun Hao , Dongmei Li , Jing Yang
J Eur Acad Dermatol Venereol. 2025 Oct;39(10):e936-e937.
PMID: 40298538 DOI: 10.1111/jdv.20710
20.生物制剂对银屑病患者焦虑抑郁症状的比较效应
Comparative effects of biologics on anxiety and depression symptoms in psoriasis
Yuxiong Jiang, Yu Wang, Dawei Huang, Min Dai, Xiaoyuan Zhong, Lingling Yao, Shuang Xu, Ying Li, Jiajing Lu, Yuling Shi
J Eur Acad Dermatol Venereol. 2025 Sep;39(9):e812-e815.
PMID: 40272021 DOI: 10.1111/jdv.20702
21.既往生物制剂暴露对特应性皮炎药物存活率的影响
Impact of prior biologic exposure on drug survival in atopic dermatitis
Xu Li, Shuang Wu , Yanfei Li, Jingxue Guo , Peng Jin , Lili Zhi
J Eur Acad Dermatol Venereol. 2025 Sep;39(9):e828-e829.
PMID: 40156232 DOI: 10.1111/jdv.20678
22.颗粒状角化不良
Granular parakeratosis
Shihui Zhou, Yifeng Guo
J Eur Acad Dermatol Venereol. 2025 Aug;39(8):1510.
PMID: 39912547 DOI: 10.1111/jdv.20574
23.结节性痒疹患者恶性肿瘤风险：系统评价与荟萃分析
Risk of malignancy in patients with prurigo nodularis: A systematic review and meta-analysis
Po-Yen Chang , Hsien-Yi Chiu
J Eur Acad Dermatol Venereol. 2025 Aug;39(8):e716-e719.
PMID: 39817665 DOI: 10.1111/jdv.20531
24.基于网络预测方法鉴定肢端黑色素瘤中两种分子及预后特征不同的亚型
Identification of two molecularly and prognostically distinct subtypes in acral melanoma using network prediction method
Mingzhu Yin, Yiding Zhang , Wenhua Wang , Shuang Zhao , Juan Su , Shao Li , Xiang Chen
J Eur Acad Dermatol Venereol. 2025 Jul;39(7):1254-1266.
PMID: 39282977
PMCID: PMC12188512
DOI: 10.1111/jdv.20335
25.大疱性类天疱疮患者功能衰退的探讨
Probing into functional decline among bullous pemphigoid patients
Wei-Zhen Tang , Kang-Jin Huang , Tai-Hang Liu
PMID: 39625222 DOI: 10.1111/jdv.20469
26.关于‘超越记分牌：教练对户外运动中紫外线相关皮肤癌的认知’的评论
Comment on 'Beyond the scoreboard: Coaches' UV-related skin cancer knowledge in outdoor sports'
Luo-Wei Chan , Shih-Hao Huang , Jian-Chih Chen, Chia-Hao Hsu
J Eur Acad Dermatol Venereol. 2025 Jul;39(7):e642-e643.
PMID: 39912336 DOI: 10.1111/jdv.20567
27.IL-24与大疱性类天疱疮严重程度的关联：一项病例对照研究
IL-24 for bullous pemphigoid severity: A case-control study
Yutong Ran , Xueting Peng , Yumin Xia , Yale Liu
J Eur Acad Dermatol Venereol. 2025 Jun;39(6):e511-e513.
PMID: 39648873 DOI: 10.1111/jdv.20467
28.佩索利单抗治疗难治性儿童Hallopeau肢端皮炎连续病例系列报告
Spesolimab in refractory paediatric acrodermatitis continua of Hallopeau, a case series
Liting Cai , Yunling Yan , Yang Li , Junjie Lin , Xinyan She , Xiaohua Wang
J Eur Acad Dermatol Venereol. 2025 Jun;39(6):e526-e528.
PMID: 39679631 DOI: 10.1111/jdv.20500
29.银屑病患者与医师对疾病活动度评估的差异：言语登记研究
Disagreement between physicians' and patients' assessment of disease activity in psoriasis: The SPEECH registry study
Yuxiong Jiang, Xiaoke Liu, Lingling Yao, Dawei Huang, Xiaoyuan Zhong, Yu Wang, Ying Li, Jiajing Lu, Qian Yu, Yuling Shi
J Eur Acad Dermatol Venereol. 2025 Jun;39(6):e470-e472.
PMID: 39520223 DOI: 10.1111/jdv.20428
30.抗IL-36受体单克隆抗体Recibokibart治疗泛发性脓疱性银屑病：1b期临床试验
Recibokibart, an anti-IL-36 receptor monoclonal antibody, for treating generalized pustular psoriasis: Phase 1b trial
Qiaoxia Qian, Baoqi Yang, Xueyan Lu , Zhaoxia Zhang , Jiaqi Chen , Yehong Kuang , Chunlei Zhang , Xiaoyong Man , Juan Su , Chi Ma , Guodong Zhou , Benke Li , Xiaolu Situ , Xiuqiang Ma , Yongming Yang , Yujie Feng , Shi Chen , Yifan Zhan , Qian Chen , Xiangyang Zhu , Jiucun Wang, Furen Zhang
J Eur Acad Dermatol Venereol. 2025 Jun;39(6):e544-e546.
PMID: 39754490
PMCID: PMC12105414
DOI: 10.1111/jdv.20511
31.恶性梅毒：二期梅毒的罕见表现
Syphilis maligna: Uncommon presentation of secondary syphilis
Hui-En Chuo , Yu-Hung Wu
J Eur Acad Dermatol Venereol. 2025 Jun;39(6):1192.
PMID: 39927700 DOI: 10.1111/jdv.20593
32.迈向更全面的评估：解决度普利尤单抗研究与妊娠结局之间的局限性
Towards a more comprehensive evaluation: Addressing limitations in the study of dupilumab and pregnancy outcomes
Lei Zhang, Ziyi Wang, Jun Li , Yaling Li
J Eur Acad Dermatol Venereol. 2025 Jun;39(6):e558-e559.
PMID: 39898753 DOI: 10.1111/jdv.20572
33.Q开关亚历山大石激光联合局部雷帕霉素治疗22例激光难治性面部咖啡因斑
Q-switched alexandrite laser combined with topical rapamycin in 22 patients with laser-resistant facial café-au-lait macules
Xumei Wu, Chaoyang Miao, Yuanxiang Liu, Xinrong Zhao, Yimeng Zhang, Zigang Xu
J Eur Acad Dermatol Venereol. 2025 Jun;39(6):e482-e484.
PMID: 39564867 DOI: 10.1111/jdv.20413
34.中国男男性行为者中沙眼衣原体的感染与基因型分布：一项全国性社区研究
Infections and genotypes of Chlamydia trachomatis among men who have sex with men in China: A nationwide community-based study
Ting-Ting Jiang, Ning-Xiao Cao, Wan-Yue Zhang , Xing-Dong Ye , Yu-Mao Cai , Min-Zhi Wu , Ai-Li Li , Zhan-Feng Han , Yi Zheng , Hai-Bo Ding,Li-Qin Gu,Hong-Chun Liao,Li Yan,Quan Luo , Yun-Qing Yang , Mei-Qin Shi, Yan Han , Yue-Ping Yin, Xiang-Sheng Chen
J Eur Acad Dermatol Venereol. 2025 Jun;39(6):e520-e523.
PMID: 39666450 DOI: 10.1111/jdv.20487
35.关于痤疮治疗中皮肤科化妆品使用建议的国际专家共识
International expert consensus recommendations for the use of dermocosmetics in acne
Diane Thiboutot , Alison M Layton , Ibrahima Traore , Gabriel Gontijo , Patricia Troielli , Qiang Ju , Ichiro Kurokawa , Brigitte Dreno
J Eur Acad Dermatol Venereol. 2025 May;39(5):952-966.
PMID: 38877766
PMCID: PMC12023719
DOI: 10.1111/jdv.20145
36.局部使用4%米诺环素泡沫剂（FMX101）治疗中国中重度寻常痤疮受试者的疗效与安全性：一项3期、多中心、随机、双盲、载体对照研究
Efficacy and safety of topical minocycline foam (FMX101 4%) in treatment of Chinese subjects with moderate-to-severe facial acne vulgaris: A phase , multi-centre, randomized, double-blind, vehicle-controlled study
Yan Le , Wenlin Yang , Jianyun Lu , Xian Jiang , Qing Guo , Chunyun Huang , Qing Sun , Huiping Wang , Mingye Bi , Haiying Wang , Songmei Geng,Bin Yang,Ai-E Xu,Yong Cui,Xiaoyong Man,Yi Zhao,Litao Zhang,Linfeng Li,Zhiqiang Song,Jin Chen,Hao Cheng,Wei Zhu,Xiuping Han,Shanshan Li,Tong Lin,Chunlei Zhang,Jiuhong Li,Yanling Li,Yangfeng Ding,Linda Wang,Yuefang Zhu,Leihong Xiang
J Eur Acad Dermatol Venereol. 2025 May;39(5):967-975.
PMID: 38948962 DOI: 10.1111/jdv.20159
37.对《增强多模态深度学习以提高医学诊断的精确性和效率》的回应
Response to 'Enhancing multimodal deep learning for improved precision and efficiency in medical diagnostics'
Kaili Chen , Zhi Yang , Qianwen Li , Hai Long , Rong Xiao , Kai Hu , Haijing Wu , Qianjin Lu
J Eur Acad Dermatol Venereol. 2025 May;39(5):e453-e455.
PMID: 39305063 DOI: 10.1111/jdv.20347
38.提升黑色素瘤评估HFUS准确性：人工智能与统计精确度的作用
Enhancing HFUS accuracy in melanoma assessment: The role of artificial intelligence and statistical precision
I Chen , S Yu
J Eur Acad Dermatol Venereol. 2025 May;39(5):e460-e461.
PMID: 39501656 DOI: 10.1111/jdv.20419
39.阿布昔替尼治疗结节性痒疹的临床疗效与安全性特征
Abrocitinib for prurigo nodularis: Clinical efficacy and safety profile
Changchun Wang, Quanhong Zhang, Lang Yu, Liuqing Chen, Jinbo Chen
J Eur Acad Dermatol Venereol. 2025 Apr;39(4):e344-e346.
PMID: 39264711 DOI: 10.1111/jdv.20322
40.H1抗组胺药诱发的反常性荨麻疹的诊断检查
Diagnostic workup in paradoxical urticaria induced by H1-antihistamines
Yi-Kui Xiang, Emek Kocatürk
J Eur Acad Dermatol Venereol. 2025 Apr;39(4):723-724.
PMID: 40130384
PMCID: PMC11934000
DOI: 10.1111/jdv.20523
41.接受利妥昔单抗治疗的天疱疮患者长期完全缓解的相关因素
Factors associated with long-term complete remission in pemphigus patients receiving rituximab therapy
Hao-Chen Hsu , Po-Wei Huang, Yung-Tsu Cho , Chia-Yu Chu
J Eur Acad Dermatol Venereol. 2025 Apr;39(4):e313-e316.
PMID: 39150314 DOI: 10.1111/jdv.20290
42.佩索利单抗治疗Netherton综合征
Treatment of Netherton syndrome with spesolimab
Juan Bai , Xinyi Chen , Jianjun Qiao , Hong Fang
J Eur Acad Dermatol Venereol. 2025 Mar;39(3):e261-e262.
PMID: 39073211 DOI: 10.1111/jdv.20244
43.奥法妥木单抗与全身性皮质类固醇联合治疗天疱疮的疗效评估：一项多中心队列研究
Evaluation of combination therapy with ofatumumab and systemic corticosteroids for pemphigus: A multi-centre cohort study
Jing Mao, Siyi Bao, Ying Chen, Zheyu Zhuang , Wenyun Chen , Guomin Li , Zhili Wu , Shiling Geng , Haiqing Wang , Hui Ke, Qiuyun Xu , Niu Xiang , Ying Zou , Zhuo Liu , Lihong Chen , Xia Xiong , Bo Cheng , Ruzeng Xue , Ting Gong , Chao Ji
J Eur Acad Dermatol Venereol. 2025 Mar;39(3):e244-e247.
PMID: 38994899 DOI: 10.1111/jdv.20245
44.阿布昔替尼与度普利尤单抗在成人特应性皮炎患者中的药物生存率比较
Drug survival of abrocitinib compared to dupilumab in adult patients with atopic dermatitis
Qingjie Hu , Yingxia Gao , Kang Xu , Xu Yao
J Eur Acad Dermatol Venereol. 2025 Mar;39(3):e269-e270.
PMID: 39072802 DOI: 10.1111/jdv.20265
45.穿孔移植可作为白癜风黑素细胞移植后病灶周围晕的辅助治疗
Punch grafting can be used as a supplementary treatment for perilesional halo after melanocyte grafting for vitiligo
Xian Yan Luo , Yun Zhi Zhao , Jian Zhong Peng , Yong Hu , Wen Jia Yang , Aie Xu
J Eur Acad Dermatol Venereol. 2025 Mar;39(3):e258-e260.
PMID: 39032071 DOI: 10.1111/jdv.20252
46.口服托法替布、巴瑞替尼和乌帕替尼单药治疗类固醇抵抗性白癜风：一项前瞻性病例系列研究
Oral tofacitinib, baricitinib and upadacitinib monotherapy for steroid-resistant vitiligo: A prospective case series
Yijian Zhu , Zhengzhou Shi , Zhongyi Xu , Suqing Liu , Jian Zhang , Qianqian Wang , Ye Liu , Chengfeng Zhang , Min Jiang , Leihong Xiang
J Eur Acad Dermatol Venereol. 2025 Feb;39(2):e128-e130.
PMID: 38853646 DOI: 10.1111/jdv.20109
47.朗格汉斯细胞：特应性皮炎病理生理学的核心参与者
Langerhans cells: Central players in the pathophysiology of atopic dermatitis
Yi Pan, Mathias Hochgerner , Małgorzata Anna Cichoń , Theresa Benezeder , Thomas Bieber, Peter Wolf
J Eur Acad Dermatol Venereol. 2025 Feb;39(2):278-289.
PMID: 39157943
PMCID: PMC11760705
DOI: 10.1111/jdv.20291
48.评估生物制剂在银屑病合并恶性肿瘤患者中的安全性和有效性：见解与未来方向
Evaluating the safety and efficacy of biologics in psoriatic patients with malignancies: Insights and future directions
Sebastian Yu, James Cheng-Chung Wei
J Eur Acad Dermatol Venereol. 2025 Feb;39(2):e191-e192.
PMID: 38932645 DOI: 10.1111/jdv.20195
49.克立硼罗局部给药改善特应性皮炎患者的度普利尤单抗面部皮炎：一项开放标签病例系列研究
Dupilumab facial dermatitis in atopic dermatitis patients ameliorated by topical crisaborole: An open-label case series study
Han-Wen Lin, Wen-Hung Chung, Chun-Bing Chen
J Eur Acad Dermatol Venereol. 2025 Feb;39(2):e181-e183.
PMID: 39105558 DOI: 10.1111/jdv.20281
50.视黄酸通过Wnt/β-连环蛋白信号通路驱动雄激素性脱发中毛囊干细胞的活化
Retinoic acid drives hair follicle stem cell activation via Wnt/β-catenin signalling in androgenetic alopecia
Lihong Wen, Zhexiang Fan , Weichang Huang , Yong Miao , Jiarui Zhang , Bingcheng Liu , Decong Zhu , Damao Dai , Jiaxian Zhang , Demengjie Le , Yufan Zhang , Qian Qu , Zhiqi Hu , Ruosi Chen
J Eur Acad Dermatol Venereol. 2025 Jan;39(1):189-201.
PMID: 38629345
PMCID: PMC11664453
DOI: 10.1111/jdv.20000
52.巴瑞替尼治疗儿童严重斑秃
Baricitinib therapy for paediatric patients with severe alopecia areata
Min Zhao , Yi Wei , Lu Cai , Jia Zhuo , Zhongyu Zhang , Mao Lin
J Eur Acad Dermatol Venereol. 2025 Jan;39(1):e82-e83.
PMID: 38775417 DOI: 10.1111/jdv.20108
53.基于专家共识和分布特征的大型至巨大先天性黑素细胞痣最佳分类系统
A BEST classification system of large to giant congenital melanocytic nevi based on expert consensus and distribution characteristics
Ge Song, Tao Dai , Yajie Chang , Huile Pei , Wuping Liu , Pengfei Guo , Yongqiang Ren , Guiping Shen , Jianghua Feng
J Eur Acad Dermatol Venereol. 2025 Jan;39(1):171-180.
PMID: 38708780 DOI: 10.1111/jdv.20075
54.探究AP1B1相关KIDAR综合征中Th17相关炎症反应及司库奇尤单抗的潜在治疗意义
Exploring Th17-related inflammation in AP1B1-associated KIDAR syndrome and potential therapeutic implications of secukinumab
Chaolan Pan, Hongsong Ge , Luyao Zheng , Qiaoyu Cao , Cheng Zhang , Yumeng Wang, Anqi Zhao, Wei He , Guofang Li, Haifei Liu, Yijun Yang, Ruoqu Wei, Haoyu Wang, Yidong Tan, Bing Wang, Wenjie Cheng, Zhe Sun, Xiaoxiao Wang , Ming Li
J Eur Acad Dermatol Venereol. 2025 Jan;39(1):e13-e16.
PMID: 38641987 DOI: 10.1111/jdv.20033
55.乌帕替尼治疗由NIPAL4变异引起的常染色体隐性遗传性先天性鱼鳞病
Treatment of autosomal recessive congenital ichthyosis caused by a NIPAL4 variant with upadacitinib
Zhuoqing Gong, Yu Wang , Xingyuan Jiang , Huijun Wang , Zhimiao Lin
J Eur Acad Dermatol Venereol. 2025 Jan;39(1):e91-e93.
PMID: 38808853 DOI: 10.1111/jdv.20130
56.全基因组测序揭示中国家族中与Bazex-Dupre-Christol综合征相关的Xq26.1基因间重复序列
Whole genome sequencing revealing Xq26.1 intergenic duplications associated with Bazex-Dupré-Christol syndrome in a Chinese family
An-Qi Zhao, Zhen-Zhen Wang, Sheng-Li Chen, Hong Liu
J Eur Acad Dermatol Venereol. 2025 Jan;39(1):e46-e49.
PMID: 38713094 DOI: 10.1111/jdv.20064
2025年度JID合集列表
（最新IF：5.7）
1.多组学分析揭示寻常痤疮的遗传机制与治疗靶点
Multi-Omics Analysis Identifies Genetic Mechanisms and Therapeutic Targets for Acne Vulgaris
Xinlan Qiu, Yibo Feng, Xiaohui Mo, Qiang Ju
J Invest Dermatol. 2025 Dec;145(12):3037-3050.
PMID: 40398594 DOI: 10.1016/j.jid.2025.04.032
2.中国人群手部湿疹的临床特征及其与特应性皮炎的关联：一项多中心横断面研究
Clinical Characteristics of Hand Eczema and its Association with Atopic Dermatitis in the Chinese Population: A Multicenter Cross-Sectional Study
Junfen Zhang, Yixin Yu, Peizhen Zhao, Liyan Yuan, Xuan Wang, Jingjing Gu, Fei Hao, Gang Wang, Qianjin Lu, Hengjin Li, Jie Zheng, Furen Zhang, Wei Lai, Hongzhong Jin, Xiaoming Liu, Qing Sun, Qing Guo, Liuqing Chen, Yan Ding, Xiaojing Kang, Jie Li, Yuye Li, Yumei Liu, Chengzhi Lv, Shuqing Mei, Zhiqiang Song, Jianqin Wang, Ting Xiao, Wenlin Yang, Xu Yao, Ying Zou, Yunsheng Liang, Bin Yang
J Invest Dermatol. 2025 Dec;145(12):3089-3099.e7.
PMID: 40398595 DOI: 10.1016/j.jid.2025.04.031
3.微针介导的甲氨蝶呤皮内递送通过抑制IL-17A+Vγ4+γδT细胞缓解咪喹莫特诱导的初始及复发性银屑病样皮肤炎症
Microneedle-Mediated Intradermal Delivery of Methotrexate Alleviates Imiquimod-Induced Initial and Recurrent Psoriasis-Like Skin Inflammation by Inhibiting IL-17A+Vγ4+ γδT Cells
Hongyao Du, Jing Yang, Pei Liu, Liang Zhao, Yan Li, Lianbin Zhang, Jintao Zhu, Juan Tao
J Invest Dermatol. 2025 Dec;145(12):3227-3231.e6.
PMID: 40571155 DOI: 10.1016/j.jid.2025.05.039
4.非性激素在女性型脱发发病机制中的新作用
A New Role of Non-Sex Hormone in the Pathogenesis of Female Pattern Hair Loss
Tyng-Shiuan Hsieh, Wei-Hung Wang, Sung-Jan Lin
J Invest Dermatol. 2025 Dec;145(12):2930-2932.
PMID: 40844442 DOI: 10.1016/j.jid.2025.06.1595
5.Piezo1介导的钙离子流将机械信号传递至Yes相关蛋白以刺激瘢痕疙瘩基质生成
Piezo1-Mediated Calcium Flux Transfers Mechanosignal to Yes-Associated Protein to Stimulate Matrix Production in Keloid
Caihe Liao, Peiru Wang, Qingyu Zeng, Guorong Yan, Jiawen Gao, Jia Liu, Jia Yan, Guolong Zhang, Yeqiang Liu, Xiuli Wang
J Invest Dermatol. 2025 Nov;145(11):2869-2881.e9.
PMID: 40254148 DOI: 10.1016/j.jid.2025.03.039
6.协同靶向TGF-β1/SMAD2信号通路治疗雄激素性脱发
miR-574-3p and miR-125a-5p in Adipose-Derived Mesenchymal Stem Cell Exosomes Synergistically Target TGF-β1/SMAD2 Signaling Pathway for the Treatment of Androgenic Alopecia
Cong Ma, Ming Cheng, Ting Xiao, Ruiqun Qi, Xinghua Gao, Hongduo Chen, Yan Wu, Xuegang Xu
J Invest Dermatol. 2025 Nov;145(11):2719-2735.e3.
PMID: 40306482 DOI: 10.1016/j.jid.2025.03.042
7.中国皮肤白化病患者TYR变异效应的多重检测与再分类
Multiplexed Assays of Variant Effect and Reclassification of TYR Variants in Chinese Patients with Oculocutaneous Albinism
Shushu Lv, Zhenhua Hao, Wei Li, Aihua Wei
J Invest Dermatol. 2025 Nov;145(11):2798-2810.e5.
PMID: 40252993 DOI: 10.1016/j.jid.2025.03.038
8.提升银屑病与炎症性皮肤病的诊断水平：一种整合临床与皮肤镜图像的空间对齐多模态模型
Enhancing Diagnosis of Psoriasis and Inflammatory Skin Diseases: A Spatially Aligned Multimodal Model Integrating Clinical and Dermoscopic Images
Juncheng Wang, Yilan Zhang, Fengying Xie, Jie Liu
J Invest Dermatol. 2025 Nov;145(11):2736-2744.e6.
PMID: 40216156 DOI: 10.1016/j.jid.2025.03.034
9.探索年轻成年女性早发性白发的危险因素：一项在中国上海开展的横断面研究
Exploring the Risk Factors for Premature Hair Graying in Young Adult Women: A Cross-Sectional Study in Shanghai, China
Wen-Cai Jiang, Hui Zhang, Ya-Fei Xu, Hai-Mei Kong, Yi-Mei Tan, Da-Ru Lu
J Invest Dermatol. 2025 Nov;145(11):2882-2885.e4.
PMID: 40387682 DOI: 10.1016/j.jid.2025.03.027
10.耐受性单核细胞来源的朗格汉斯细胞通过芳烃受体-环氧合酶-2激活促进黑色素瘤进展及免疫治疗耐药
Tolerogenic Monocyte-Derived Langerhans Cells Promote Melanoma Progression and Immunotherapy Resistance through Aryl Hydrocarbon Receptor-Cyclooxygenase-2 Activation
Liyun Dong, Naming Wu, Zhen Cai, Shiyi Yan, Juan Pan, Liu Yang, Jinjin Zhu, Yujue Wang, Jun Li, Juan Tao
J Invest Dermatol. 2025 Nov;145(11):2828-2838.e10.
PMID: 40216154 DOI: 10.1016/j.jid.2025.02.155
11.内皮Piezo1介导银屑病中屏障功能障碍与NLRP3炎症小体激活
Endothelial Piezo1 Mediates Barrier Dysfunction and NLRP3 Inflammasomes Activation in Psoriasis
Lixin Yue, Bingyu Pang, Guohao Li, Chen Zhang, Qingyang Li, Kang Li, Hui Fang, Zhenlai Zhu, Shuai Shao, Erle Dang, Gang Wang, Pei Qiao
J Invest Dermatol. 2025 Oct;145(10):2484-2494.e5.
PMID: 40054572 DOI: 10.1016/j.jid.2025.01.037
12.瘢痕疙瘩形成中的内皮功能障碍及其治疗启示
Endothelial Dysfunction in Keloid Formation and Therapeutic Insights
Junxian Wen, Zhijin Li, Yingrou Tan, Hong Liang Tey, Nanze Yu, Xiaojun Wang
J Invest Dermatol. 2025 Oct;145(10):2436-2448.
PMID: 40100176 DOI: 10.1016/j.jid.2025.02.134
13.USP7介导的泛素化稳定JunD并激活AIFM2（FSP1）以抑制黑色素瘤铁死亡
Deubiquitination by USP7 Stabilizes JunD and Activates AIFM2 (FSP1) to Inhibit Ferroptosis in Melanoma
Jiaheng Xie, Chenfeng Ma, Songyun Zhao, Dan Wu, Pengpeng Zhang, Qikai Tang, Tianyi Ni, Wei Yan, Min Qi
J Invest Dermatol. 2025 Oct;145(10):2562-2575.e5.
PMID: 40187679 DOI: 10.1016/j.jid.2025.03.018
14.情绪困扰与特应性皮炎的关联性：一项横断面研究
Association between Emotional Distress and Atopic Dermatitis: A Cross-Sectional Study
Hanyi Zhang, Siding Tang, Xiang Chen, Mi Wang, Juan Su
J Invest Dermatol. 2025 Oct;145(10):2613-2615.e1.
PMID: 40139563 DOI: 10.1016/j.jid.2025.03.007
15.基底外侧杏仁核至内侧前额叶皮层的谷氨酸能投射参与急性瘙痒感觉处理
Glutamatergic Projections from the Basolateral Amygdala to Medial Prefrontal Cortex Contribute to Acute Itch Sensation Processing
Qiuying Zhao, Ze Fan, Yiwen Zhang, Jiaqi Li, Yuanyuan Zhu, Yiting Lin, Qingrong Ni, Xiaotong Shi, Ling Liu, Shengxi Wu, Jing Huang
J Invest Dermatol. 2025 Oct;145(10):2588-2597.
PMID: 40043789 DOI: 10.1016/j.jid.2025.02.138
16.血转录组特征作为阿布昔替尼治疗特应性皮炎的疗效指标与预测因子
Blood Transcriptome Signature as Indicator and Predictor for Efficacy of Abrocitinib in Treatment of Atopic Dermatitis
Yu Wang, Huibin Yin, Zheng Li, Hao Wu, Qianhao Wang, Xingyu Chen, Liya Mao, Yuemeng Wu, Shangshang Wang, Haihong Qin, Chaoying Gu, Xu Yao, Wei Li
J Invest Dermatol. 2025 Oct;145(10):2524-2534.e5.
PMID: 40058571 DOI: 10.1016/j.jid.2025.02.145
17.基于人工智能模型的银屑病患者体表面积精确测量方法开发
Development of an Artificial Intelligence-Based Model to Precisely Measure Body Surface Area in Psoriasis
Yiyi Wang, Xuhao Wang, Xinran Ming, Yuanxia Gu, Qian Wang, Mingzheng Zhu, Lin Qin, Furong Li, Yue Xiao, Hongxiang Hu, Chenlin Du, Yue Zhang, Mingyue Zhang, Ranjie Hu, Wei Li
J Invest Dermatol. 2025 Oct;145(10):2600-2602.e6.
PMID: 40158769 DOI: 10.1016/j.jid.2025.03.013
18.与银屑病发病机制相关的记忆辅助性T细胞和记忆调节性T细胞的转录组及染色质景观变化
Transcriptome and Chromatin Landscape Changes Associated with Pathogenesis of Psoriasis in Memory T Helper and Memory Regulatory T Cells
Mengyun Chen, Min Chen, Lu Liu, Pengcheng Yan, Ziyuan Meng, Tingting Zhu, He Huang, Weiran Li, Xuejun Zhang, Zheng Zhang, Bo Zhang
J Invest Dermatol. 2025 Oct;145(10):2606-2609.e6.
PMID: 40187680 DOI: 10.1016/j.jid.2025.03.019
19.5-氨基酮戊酸光动力疗法通过蛋白激酶B/JunD介导的NR4A1激活调节脂质生成治疗寻常痤疮
The 5-Aminolevulinic Acid Photodynamic Therapy Modulates Lipid Production by Protein Kinase B/JunD-Mediated NR4A1 Activation in the Treatment of Acne Vulgaris
Yun Wu , Xiaojing Liu , Linglin Zhang , Peiru Wang , Haiyan Zhang , Jia Yan , Yu Yan , Pei Liu , Jingjun Zhao , Qingyu Zeng , Xiuli Wang
J Invest Dermatol. 2025 Sep;145(9):2179-2190.e2.
PMID: 39922453 DOI: 10.1016/j.jid.2025.01.018
20.寻常痤疮多组学研究进展:文献综述
Progress on Multiomics Research on Acne Vulgaris: A Literature Review
Yangfan Lai , Mengjie Fan , Xiaoyao Fan , Jin Chen , Leihong Flora Xiang , Ying Ma
J Invest Dermatol. 2025 Sep;145(9):2162-2169.
PMID: 40146096 DOI: 10.1016/j.jid.2025.02.012
21.银屑病文献研究热点与趋势识别：基于Agent的自动调谐主题建模
Identifying Research Hotspots and Trends in Psoriasis Literature: Autotuned Topic Modeling with Agent
Sunsi Wu , Dan Wang , Xinpei Gu , Ruiheng Xiao , Hongzhi Gao , Bo Yang , Yanlan Kang
J Invest Dermatol. 2025 Sep;145(9):2210-2218.e14.
PMID: 39894203 DOI: 10.1016/j.jid.2024.11.029
22.网状细胞与角质形成细胞串扰在皮肤免疫中的作用
The Role of Crosstalk between Nets and Keratinocytes in Skin Immunity
Xiao Zhou , Yi Jin , Yanshan Zhu , Xin Luo , Siying Li , Weiyun Shen , Ruifang Wu
J Invest Dermatol. 2025 Aug;145(8):1866-1878.
PMID: 39985552 DOI: 10.1016/j.jid.2024.07.040
23.表皮机械搔抓诱导的活性氧通过激活肥大细胞上的TRPA1加剧特应性皮炎的瘙痒-搔抓循环
Epidermal Mechanical Scratching-Induced ROS Exacerbates the Itch-Scratch Cycle through TRPA1 Activation on Mast Cells in Atopic Dermatitis
Jiahui Hu , Qiang Zhao , Delu Che , Bin Peng , Xi Wang , Kathy Wang , Li Li , Songmei Geng
J Invest Dermatol. 2025 Aug;145(8):2034-2048.e7.
PMID: 39892773 DOI: 10.1016/j.jid.2024.12.026
24.下调的TFPI2通过磷酸肌醇3-激酶/蛋白激酶B/CDC6通路抑制细胞周期从而加速皮肤衰老
Downregulated TFPI2 Accelerates Skin Aging by Repressing the Cell Cycle through Phosphoinositide 3-Kinase/Protein Kinase B/CDC6 Pathway
Fan Wang , Caitan Yi , Yun Zhong , Lei Zhou , Xin Meng , Rui Mao , Yi Guo , Hongfu Xie , Yiya Zhang , Yingxue Huang , Ji Li
J Invest Dermatol. 2025 Aug;145(8):1910-1920.e7.
PMID: 39848565 DOI: 10.1016/j.jid.2024.11.028
25.先天性大/巨黑素细胞痣与卫星痣关系的探讨
Insight into the Relationship between Congenital Large/Giant Melanocytic Nevi and Satellite Nevi
Jieyu Gu , Boxuan Wei , Ran Duan , Jiamin Jin , Bohan Lai , Jiao Wei , Feng Xie
J Invest Dermatol. 2025 Aug;145(8):2071-2074.e2.
PMID: 39890054 DOI: 10.1016/j.jid.2024.10.620
26.重度痤疮家族的全基因组结构变异研究
Whole-Genome Structural Variations Study in a Severe Acne Family
Jiaqi Feng , Mingmin Xu , Jue Qi , Wenjuan Wu , Minsheng Peng , Li He
J Invest Dermatol. 2025 Aug;145(8):2098-2102.e5.
PMID: 39952348 DOI: 10.1016/j.jid.2025.01.023
27.革新慢性伤口治疗：采用三维生物打印皮肤替代物治疗博来霉素病灶内注射相关慢性伤口
Revolutionizing Chronic Wound Treatment: Treating Bleomycin Intralesional Injection-Related Chronic Wounds with 3-Dimensional Bioprinted Skin Substitutes
Mengde Zhang , Zhao Li , Rungong Yang , Liting Liang , Yuyan Huang , Chao Zhang , Yaxin Tan , Yuzhe Bai , Xiaobing Fu , Sha Huang
J Invest Dermatol. 2025 Aug;145(8):2111-2114.e7.
PMID: 39800166 DOI: 10.1016/j.jid.2024.12.018
28.表皮功能障碍在炎症衰老发病机制中的作用与意义
The Role and Implications of Epidermal Dysfunction in the Pathogenesis of Inflammaging
Jiechen Zhang , Bijun Xia , Joan S Wakefield , Peter M Elias , Xiaohua Wang
J Invest Dermatol. 2025 Jul;145(7):1580-1588.
PMID: 39808093 DOI: 10.1016/j.jid.2024.09.025
29.低密度中性粒细胞水平与孢子丝菌病严重程度相关：皮下真菌感染的深入研究
Low-Density Neutrophil Levels Are Correlated with Sporotrichosis Severity: Insights into Subcutaneous Fungal Infection
Ying Shi , Yuan-Yuan Liu , Yu Zhen , He-Nan Si , Meng-Qi Guan , Yan Cui , Shan-Shan Li
J Invest Dermatol. 2025 Jul;145(7):1753-1769.e3.
PMID: 39603410 DOI: 10.1016/j.jid.2024.10.610
30.光与影之间：白癜风非病灶皮肤的谜团
Between Light and Shadow: The Enigma of Nonlesional Skin in Vitiligo
Yijian Zhu , Chengfeng Zhang
J Invest Dermatol. 2025 Jul;145(7):1547-1549.
PMID: 40257415 DOI: 10.1016/j.jid.2025.02.011
31.血管紧张素转换酶抑制剂与皮肤纤维化风险无因果关联：孟德尔随机化证据
No Causal Association between Angiotensin-Converting Enzyme Inhibitors and Skin Fibrosis Risk: Evidence from Mendelian Randomization
Yangyang Wei , Ziqi Wan , Yiwen Jiang , Zhengye Liu , Ming Yang , Jieying Tang
J Invest Dermatol. 2025 Jul;145(7):1808-1810.e3.
PMID: 39814197 DOI: 10.1016/j.jid.2024.12.020
32.雄激素性脱发与中国重症急性呼吸综合征冠状病毒2 Omicron变异株感染的相关性
Correlation between Androgenetic Alopecia and Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Infection in China
Shuying Lv , Xiaohui Zou , Lei Wang , Yonglong Xu , Chuhan Huang , Shiyi Zhong , Wenjun Lin , Ying Xie , Huijuan Fang , Meijiao Du , Yunran Cui , Ruiying Wu , Yuqi Jiang , Mingyue Zhuang , Jieping Huang , Dingquan Yang
J Invest Dermatol. 2025 Jul;145(7):1633-1642.e6.
PMID: 39725159 DOI: 10.1016/j.jid.2024.11.013
33.头皮屑患者头皮微生物氨基酸代谢异常及发病机制
Abnormal Microbial Amino Acid Metabolism and Activated Pathogenesis in Scalp with Dandruff
Zhijue Xu , Fang Yang , Baoyu Xiang , Xiaowei Chang , Dandan Xia , Yaoyao Wu , Yan Zhang , Menghui Zhang
J Invest Dermatol. 2025 Jul;145(7):1823-1826.e7.
PMID: 39842690 DOI: 10.1016/j.jid.2025.01.006
34.ADAM10/17介导的LAG3切割在银屑病免疫抑制功能障碍中的作用
Role of ADAM10/17-Mediated Cleavage of LAG3 in the Impairment of Immunosuppression in Psoriasis
Zengyang Yu , Xinyi Tang , Zeyu Chen , Yifan Hu , Shuqin Zhang , Chunyuan Guo , Jun Gu , Yuling Shi , Yu Gong
J Invest Dermatol. 2025 Jun;145(6):1385-1395.e8.
PMID: 39571889 DOI: 10.1016/j.jid.2024.10.606
35.铁死亡：黑色素瘤治疗的可靶向弱点
Ferroptosis: A Targetable Vulnerability for Melanoma Treatment
Yu Meng , Qian Zhou , Yating Dian , Furong Zeng , Guangtong Deng , Xiang Chen
J Invest Dermatol. 2025 Jun;145(6):1323-1344.
PMID: 39797894 DOI: 10.1016/j.jid.2024.11.007
36.早期阶段顶泌腺损伤及特异性角蛋白释放表明顶泌腺在化脓性汗腺炎中的关键作用
Apocrine Gland Damage and the Release of Specific Keratins in Early Stage Indicate the Crucial Involvement of Apocrine Glands in Hidradenitis Suppurativa
Jiaqi Li , Sitong Li , Qiujing Zhang , Mengchen Liang , Xiang Chen , Yibo Feng , Zhanyan Pan , Tingting Hu , Qiong Wu , Guangjie Chen , Christos C Zouboulis , Xiaohui Mo , Qiang Ju
J Invest Dermatol. 2025 Jun;145(6):1371-1384.e7.
PMID: 39547394 DOI: 10.1016/j.jid.2024.09.021
37.海藻糖通过抑制IL-33表达及增强NRF2活化，预防IL-4/IL-13在体外诱导的人角质形成细胞皮肤屏障功能障碍
Trehalose Prevents IL-4/IL-13-Induced Skin Barrier Impairment by Suppressing IL-33 Expression and Increasing NRF2 Activation in Human Keratinocytes In Vitro
Xiuju Dai , Yoichi Mizukami , Kenji Watanabe , Teruko Tsuda , Mutsumi Shidahara , Satoshi Yoshida , Kazuki Yatsuzuka , Ken Shiraishi , Hideki Mori , Masamoto Murakami , Ryosuke Kawakami , Takeshi Imamura , Yasuhiro Fujisawa , Jun Muto
J Invest Dermatol. 2025 Jun;145(6):1422-1432.e10.
PMID: 39384017 DOI: 10.1016/j.jid.2024.08.038
38.干预CCL8-CCR8信号通路可减轻小鼠皮肤炎症与瘙痒
Intervening CCL8-CCR8 Signaling Reduces Cutaneous Inflammation and Itch in Mice
Huiyuan Mei , Xiaolong Dai , Weiwei Chen , Rengang Luo , Yang Liu , Jianghui Meng , Jiafu Wang
J Invest Dermatol. 2025 Jun;145(6):1519-1523.e4.
PMID: 39761909 DOI: 10.1016/j.jid.2024.12.012
39.化脓性汗腺炎中三级淋巴组织的解码：新的机制性见解
Decoding Tertiary Lymphoid Structures in Hidradenitis Suppurativa: New Mechanistic Insights
Wei-Wen Yu , Jie Tong , Catherine P Lu
J Invest Dermatol. 2025 Jun;145(6):1272-1274.
PMID: 40152835 DOI: 10.1016/j.jid.2025.01.026
40.皮肤驻留γδ T细胞通过定向趋化迁移及细胞毒性颗粒动员介导强效选择性抗肿瘤细胞毒性
Skin-Resident γδ T Cells Mediate Potent and Selective Antitumor Cytotoxicity through Directed Chemotactic Migration and Mobilization of Cytotoxic Granules
Jiacai Yang , Zhihui Liu , Xiaohong Hu , Xiaorong Zhang , Yong Huang , Yunxia Chen , Cheng Chen , Ruoyu Shang , Yuanyang Tang , Wengang Hu , Jue Wang , Han-Ming Shen , Jun Hu , Weifeng He
J Invest Dermatol. 2025 Jun;145(6):1433-1446.e2.
PMID: 39571888 DOI: 10.1016/j.jid.2024.10.607
41.优化皮肤表面代谢组学：采样方法、提取溶剂与分析技术的综合评估
Optimizing Skin Surface Metabolomics: A Comprehensive Evaluation of Sampling Methods, Extraction Solvents, and Analytical Techniques
Huizhen Chen , Yu Chen , Yi Zhou , Shensong Cao , Jing Lu , Lianyi Han , Thomas Worzfeld , Jean Krutmann , Jiucun Wang , Jingjing Xia
J Invest Dermatol. 2025 May;145(5):1166-1179.
PMID: 39306031 DOI: 10.1016/j.jid.2024.08.027
42.解析糖尿病伤口愈合过程中成纤维细胞功能中IGF-1-SP1-CD248通路的失调机制
Deciphering the Dysregulating IGF-1-SP1-CD248 Pathway in Fibroblast Functionality during Diabetic Wound Healing
Ya-Chu Ku , Yao-Chou Lee , Yi-Kai Hong , Yung-Ling Lo , Cheng-Hsiang Kuo , Kuan-Chieh Wang , Chao-Kai Hsu , Chien-Hung Yu , Shu-Wha Lin , Hua-Lin Wu
J Invest Dermatol. 2025 May;145(5):1180-1195.
PMID: 39293711 DOI: 10.1016/j.jid.2024.07.035
43.内在调节机制保护人类皮肤肥大细胞免受MRGPRX2过度激活：LAD2（过敏性疾病实验室2）细胞中该受体的缺乏导致肥大细胞高反应性
Intrinsic Regulatory Mechanisms Protect Human Skin Mast Cells from Excessive MRGPRX2 Activation: Paucity in LAD2 (Laboratory of Allergic Diseases 2) Cells Contributes to Hyperresponsiveness of the Mast Cell Line
Zhuoran Li , Jean Schneikert , Gürkan Bal , Manqiu Jin , Kristin Franke , Torsten Zuberbier , Magda Babina
J Invest Dermatol. 2025 May;145(5):1215-1219.e4.
PMID: 39481529 DOI: 10.1016/j.jid.2024.10.593
44.TRPS1 rs12549956增强子影响中国人群的头发厚度
Enhancer of TRPS1 rs12549956 Influences Hair Thickness in Chinese Populations
Qili Qian , Sijie Wu , Junyu Luo , Yaqun Guan , Yajun Yang , Li Jin , Wenxin Zheng , Sijia Wang
J Invest Dermatol. 2025 May;145(5):1202-1205.e9.
PMID: 39547395 DOI: 10.1016/j.jid.2024.10.601
45.皮肤老化中的G蛋白偶联受体
G Protein-Coupled Receptors in Skin Aging
Suet Ting Cheung , Yelim Do , Eunah Kim , Antonella Rella , Earl Goyarts , Nadine Pernodet , Yung Hou Wong
J Invest Dermatol. 2025 Apr;145(4):749-765.e8.
PMID: 39186022 DOI: 10.1016/j.jid.2024.06.1288
46.FGF21通过抑制CK2α/GLI2信号轴改善成纤维细胞活化与系统性硬化
FGF21 Ameliorates Fibroblasts Activation and Systemic Sclerosis by Inhibiting CK2α/GLI2 Signaling Axis
Yeyi Zheng , Wenjie Gong , Zhaohang Wu , Siyi Zhang , Nan Wang , Zhenyu Hu , Yanni Shou , Tianpeng Xu , Yingjie Shen , Xiaokun Li , Litai Jin , Weitao Cong , Zhongxin Zhu
J Invest Dermatol. 2025 Apr;145(4):842-853.e8.
PMID: 39182559 DOI: 10.1016/j.jid.2024.07.026
47.解析银屑病患者外周血CD4+T细胞的三维基因组景观
Resolving 3-Dimensional Genomic Landscape of CD4+ T Cells in the Peripheral Blood of Patients with Psoriasis
Yueqi Qiu , Wenjuan Jiang , Delong Feng , Yaqin Yu , Huihui Hou , Min Deng , Xiaoyun Chen , Lin Liu , Ruifang Wu , Qianjin Lu , Ming Zhao
J Invest Dermatol. 2025 Apr;145(4):831-841.e10.
PMID: 39182560 DOI: 10.1016/j.jid.2024.08.006
48.抑制脂肪细胞源性FABP4可减轻脂肪细胞炎症、促进血管生成并加速代谢功能障碍中的伤口愈合
Inhibition of Adipocyte-Derived FABP4 Reduces Adipocyte Inflammation, Improves Angiogenesis, and Facilitates Wound Healing in Metabolic Dysfunctions
Yen-Wen Wu , Jaw-Wen Chen , Hao-Yuan Tsai , Jih-Hsin Huang , Chia-Chi Chang , Ting-Ting Chang
J Invest Dermatol. 2025 Apr;145(4):939-953.
PMID: 39260685 DOI: 10.1016/j.jid.2024.08.017
49.抑制表皮异亮氨酰-tRNA合成酶通过Jak2/信号转导与转录激活因子3/CXCL16信号通路改善银屑病样皮肤病变
Inhibition of Epidermal Isoleucyl-tRNA Synthetase Ameliorates Psoriasis-Like Skin Lesions through Jak2/Signal Transducer and Activator of Transcription 3/CXCL16 Signaling Pathway
Xi-Bei Chen , Yu-Xin Zheng , Ting-Ting Guo , Fan Xu , Ying-Zhe Cui , Lei Nie , Hai-Bin Wang , Li-Ran Ye , Ying Liu , Xing-Yu Yang , Ni-Chang Fu , Bin-Xi Yan , Min Zheng , Xiao-Yong Man
J Invest Dermatol. 2025 Apr;145(4):954-958.e8.
PMID: 39293712 DOI: 10.1016/j.jid.2024.08.021
50.Paxbp1是维持表皮稳态不可或缺的因子
Paxbp1 Is Indispensable for the Maintenance of Epidermal Homeostasis
Cong Huang , Shenglin Liu , Wenting Li , Shizheng Zhao , Xuanyao Ren , Fan Zhuo , Kaoyuan Zhang , Xiahong Li , Jingwen Wu , Zimo Zhu , Chao Chen , Wei Zhang , Bo Yu
J Invest Dermatol. 2025 Apr;145(4):864-875.e5.
PMID: 39236903 DOI: 10.1016/j.jid.2024.08.012
51.Chi3l1基因敲除可减轻小鼠慢性瘙痒及皮肤炎症
Chi3l1 Knockout Mitigates Chronic Itch and Cutaneous Inflammation in Mice
Xingyun Zhu , Xiaolong Dai , Weiwei Chen , Yanqing Li , Yang Liu , Chunxu Shan , Jiafu Wang , Jianghui Meng
J Invest Dermatol. 2025 Apr;145(4):975-979.e4.
PMID: 39366519 DOI: 10.1016/j.jid.2024.09.013
52.东亚人群指甲板形态相关基因位点
Genetic Loci Associated with Nail Plate Morphology in East Asian Populations
Jieyu Ge , Mengxiang You , Yu Fan , Yong Zhou , Li Jin , Guangtao Zhai , Fan Liu , Sijia Wang
J Invest Dermatol. 2025 Apr;145(4):969-972.e9.
PMID: 39384015 DOI: 10.1016/j.jid.2024.08.035
53.真菌分泌肽Micasin通过激活外周神经元上的MRGPRX1/C11/A1诱导瘙痒
The Fungal Secretory Peptide Micasin Induces Itch by Activating MRGPRX1/C11/A1 on Peripheral Neurons
Haifeng Yang , Yian Chen , Luyao Wang , Bing Gan , Leiye Yu , Ruobing Ren , Hang Fai Kwok , Yingliang Wu , Zhijian Cao
J Invest Dermatol. 2025 Mar;145(3):618-630.
PMID: 38945438 DOI: 10.1016/j.jid.2024.05.031
54.佩索利单抗减轻泛发性脓疱型银屑病炎症：EFFISAYIL 1中发作期治疗的分子特征
Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1
Ahmed Farag , Sudha Visvanathan , Hervé Bachelez , Akimichi Morita , Mark G Lebwohl , Jonathan N Barker , Siew Eng Choon , A David Burden , Tsen-Fang Tsai , Germán Leparc , Denis Delic , Benjamin Lang , Christian Thoma , James G Krueger
J Invest Dermatol. 2025 Mar;145(3):573-582.e8.
PMID: 39004117 DOI: 10.1016/j.jid.2024.05.034]
55.Neurturin GF增强炎症皮肤的急性细胞因子反应
Neurturin GF Enhances the Acute Cytokine Response of Inflamed Skin
Marsha Ritter Jones , James Jones , Prathyusha Pandu , Chunyan Liu , Cara D Carey , Louis D Falo , Kathryn M Albers
J Invest Dermatol. 2025 Mar;145(3):583-592.
PMID: 39122143 DOI: 10.1016/j.jid.2024.07.016
56.共生皮肤微生物群的细胞外囊泡通过重建皮肤稳态缓解特应性皮炎小鼠模型的皮肤炎症
Extracellular Vesicles of Commensal Skin Microbiota Alleviate Cutaneous Inflammation in Atopic Dermatitis Mouse Model by Re-Establishing Skin Homeostasis
Hong Zhou , Xi Tan , Guozhong Chen , Xinxin Liu , Aiping Feng , Zhi Liu , Wei Liu
J Invest Dermatol. 2025 Feb;145(2):312-322.e9.
PMID: 36907322 DOI: 10.1016/j.jid.2023.02.023
57.SERPINB7缺陷增加Nagashima型掌跖角化病中类豆蛋白酶活性并损害表皮屏障
SERPINB7 Deficiency Increases Legumain Activity and Impairs the Epidermal Barrier in Nagashima-Type Palmoplantar Keratoderma
Siyuan Li , Yingda Wu , Dingfang Bu , Linghan Hu , Yihe Liu , Juan Liu , Ruiyu Xiang , Wenbo Bu , Ran Mo , Zhongya Song , Zhiming Chen , Dongqing Li , Xue Zhang , Heng Gu , Yong Yang
J Invest Dermatol. 2025 Feb;145(2):359-369.e8.
PMID: 38909841 DOI: 10.1016/j.jid.2024.05.025
58.从结果追溯至病因：NRF2驱动的GSTA4转录调控控制特应性皮炎复发中的慢性炎症与氧化应激
Retracing from Outcomes to Causes: NRF2-Driven GSTA4 Transcriptional Regulation Controls Chronic Inflammation and Oxidative Stress in Atopic Dermatitis Recurrence
Xin Ma , Hang Zhao , Jian-Kun Song , Zhan Zhang , Chun-Jie Gao , Ying Luo , Xiao-Jie Ding , Ting-Ting Xue , Ying Zhang , Meng-Jie Zhang , Mi Zhou , Rui-Ping Wang , Le Kuai , Bin Li
J Invest Dermatol. 2025 Feb;145(2):334-345.e11.
PMID: 38879155 DOI: 10.1016/j.jid.2024.05.018
59.婴儿血管瘤发育过程中细胞命运的调控
Cell Fate Regulation During the Development of Infantile Hemangioma
Qiming Chen , Jiawei Zheng , Qian Bian
J Invest Dermatol. 2025 Feb;145(2):266-279.
PMID: 39023471 DOI: 10.1016/j.jid.2024.06.1275
60.局部应用硝酸盐通过调节系统性硬化症小鼠模型中的ST2+CD4+T细胞改善皮肤纤维化
Topical Application of Nitrate Ameliorates Skin Fibrosis by Regulating ST2+CD4+ T Cells in Systemic Sclerosis Mouse Model
Jianyu Gu , Zekun Zhou , Shihan Xu , Wen Pan , Jinsong Wang , Ousheng Liu , Songlin Wang , Junji Xu
J Invest Dermatol. 2025 Feb;145(2):346-358.e5.
PMID: 38945439 DOI: 10.1016/j.jid.2024.06.1273
61.机械牵张加剧咪喹莫特诱导性皮炎并伴随IL-1β和IL-6生成增加
Mechanical Stretch Exacerbates Imiquimod-Induced Dermatitis Associated with Increased IL-1β and IL-6 Production
Chaw-Ning Lee , Yi-Kai Hong , Hui-Ching Cheng , Wan-Yu Chi , Wei-Chen Lin , Chao-Kai Hsu , Yu-Chen Lin , Shu-Yi Cheng , Ming-Jer Tang , Chao-Chun Yang
J Invest Dermatol. 2025 Feb;145(2):436-440.
PMID: 39103118 DOI: 10.1016/j.jid.2024.07.015
62.瘢痕疙瘩潜在药物靶点的鉴定：一项孟德尔随机化研究
Identifying Potential Drug Targets for Keloid: A Mendelian Randomization Study
Yinmin Wang , Xiuxia Wang , Zhaoqi Yuan , Fei Liu , Xusong Luo , Jun Yang
J Invest Dermatol. 2025 Jan;145(1):77-84.e6.
PMID: 38797322 DOI: 10.1016/j.jid.2024.04.023
63.成纤维细胞分泌的外泌体在皮肤伤口愈合过程中调控巨噬细胞极化动态
Orchestration of Macrophage Polarization Dynamics by Fibroblast-Secreted Exosomes during Skin Wound Healing
Cheng Chen , Jiacai Yang , Ruoyu Shang , Yuanyang Tang , Xin Cai , Yunxia Chen , Zhihui Liu , Wengang Hu , Weiguang Zhang , Xiaorong Zhang , Yong Huang , Xiaohong Hu , Wenjing Yin , Qudong Lu , Hao Sheng , Dejiang Fan , Zhenyu Ju , Gaoxing Luo , Weifeng He
J Invest Dermatol. 2025 Jan;145(1):171-184.e6. d
PMID: 38838771 DOI: 10.1016/j.jid.2024.05.007
64.白癜风患者色素再生率的计算机辅助评估：对治疗效果的影响——一项回顾性研究
Computer-Aided Assessment of Repigmentation Rates in Vitiligo Patients: Implications for Treatment Efficacy - A Retrospective Study
Zheng Wang , Hui Hu , Yangyang Ou , Chong Wang , Kejuan Yue , Kaibin Lin , Jiarui Ou , Jianglin Zhang
J Invest Dermatol. 2025 Jan;145(1):56-64.e5.
PMID: 38909840 DOI: 10.1016/j.jid.2024.05.016
65.富含亮氨酸重复序列蛋白15阳性成纤维细胞的双重作用：从癌症到组织修复
The Dual Roles of Leucine-Rich Repeat-Containing Protein 15 Positive Fibroblasts: From Cancer to Tissue Repair
Honglin Zhu , Meng Meng , Hui Luo , Jörg H W Distler
J Invest Dermatol. 2025 Jan;145(1):200-204.e2.
PMID: 38987016 DOI: 10.1016/j.jid.2024.06.1279
2025年度Nature及子刊合集
（最新IF：Nature, 48.5；Nature Communications, 15.7；Nature Immunology, 27.6；Nature Genetics, 29.0；Nature Medicine, 50.0；Nature Aging, 19.4）
1. 以 IL-36/TNFSF15为核心的动态中性粒细胞-角质细胞通讯网络揭示全身性脓疱型银屑病的炎症反应特征
Dynamic neutrophil-keratinocyte communication network centered on IL-36/TNFSF15 responses characterizes inflammatory responses in generalized pustular psoriasis
Jiang R, Kirma J, Fox J, Xing X, Wang J, Sarkar MK, Bogle R, Do T, Coon A, Cole C, Plazyo O, Rew JE, Zhang H, Kahlenberg JM, Billi AC, Bachelez H, Tsoi LC, Harms PW, Shao S, Chen X, Gudjonsson JE.
Nat Commun. 2025 Dec 23. doi: 10.1038/s41467-025-67917-9. Online ahead of print.
PMID: 41436466
2.一种广谱中和抗体通过抑制gB介导的膜融合，对α疱疹病毒属实现跨属保护
A broadly neutralizing antibody confers cross-genus protection against alpha herpesviruses by inhibiting gB-mediated membrane fusion.
Wang G, Li Y, Wu C, Chen T, Gui M, Zeng Y, Sun H, Chen K, Xi X, Yang Y, Jiang Y, Jiang Y, Liu L, Yang C, Xin J, Liu C, Li Y, Huo N, Huang Y, Lin L, Yu H, Huang C, Yuan Q, Li S, Tian K, Zheng Q, Xia N, Chen Y.
Nat Commun. 2025 Dec 16;16(1):11144. doi: 10.1038/s41467-025-66099-8.
PMID: 41402251
3.人多能干细胞衍生皮肤类器官构建了结核分枝杆菌感染的病理生理模型
Human pluripotent stem cell-derived skin organoids enabled pathophysiological model of Mycobacterium tuberculosis infection.
Yue L, Liang Y, Zhong P, Fang L, Yun Z, Su Q, Li C, Xiang M, Zhang J, Wang J, Ge L, Wu C, Chen H, Qiu X, Bo X, Tan Y.
Nat Commun. 2025 Dec 2;16(1):10831. doi: 10.1038/s41467-025-65848-z.
PMID: 41331115
4.疥螨流行病学特征的估算
Estimation of the epidemiological characteristics of scabies.
Ainslie KEC, Hooiveld M, Wallinga J.
Nat Commun. 2025 Nov 26;16(1):10524. doi: 10.1038/s41467-025-65544-y.
PMID: 41298361
5.原生PMEL层状体在黑色素小体中的原子结构及原位可视化
Atomic structure and in situ visualization of native PMEL lamellae in melanosomes.
Ma B, Yao Y, Dong H, Yang L, Li D, Zhao Q, Sun B, Chen Y, Liu C, Li D.
Nat Commun. 2025 Nov 21;16(1):10300. doi: 10.1038/s41467-025-65221-0.
PMID: 41271718
6.用于复制人皮肤纹理的发光纳米纤维
Luminescent nanofibers for human skin textures photocopying.
Tian T, Han H, Lin X, Kang H, Yang M, Chen Z, Wu C, Jiang Y, Li W, Chang X, Xu Q, Zhang Y, Chen YX, Ouyang G, Pang H.
Nat Commun. 2025 Nov 4;16(1):9720. doi: 10.1038/s41467-025-64703-5.
PMID: 41188229
7.系统证据分级评估白癜风的多系统相关性与风险
Systematic evidence grading evaluates multisystemic associations and risks of vitiligo.
Liu L, Xue Y, Liu W, Cui J, Lv H, Chang J.
Nat Commun. 2025 Nov 3;16(1):9665. doi: 10.1038/s41467-025-64653-y.
PMID: 41184267
8.III/IV期黑色素瘤辅助用纳武利尤单抗与瑞拉利单抗：随机III期RELATIVITY-098试验
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.
Long GV, Garnett-Benson C, Dolfi S, Ascierto PA, Guo J, Tarhini AA, Chandra S, Muñoz-Couselo E, Del Vecchio M, de Melo AC, Callahan M, Gogas H, Dummer R, Schadendorf D, Koelblinger P, Quereux G, Thomas I, Yu JX, Fisher A, Wang B, Djidel P, Chouzy A, Semaan M, Chen B, Cheong AMY, Tawbi HA.
Nat Med. 2025 Dec;31(12):4301-4309. doi: 10.1038/s41591-025-04032-8. Epub 2025 Oct 18.
PMID: 41109920
9.人类银屑病及角质形成细胞特异性Ube2l3缺失小鼠的单细胞转录组学揭示 CXCL16/CXCR6在银屑病发展中的作用
Single cell transcriptomics of human psoriasis and epidermal specific Ube2l3 deficient mice highlight CXCL16/CXCR6 involvement in psoriasis development.
Chen XY, Ye LR, Fu NC, Chen SQ, Yan BX, Zheng YX, Chen XB, Zhou Y, Lv MY, Cui YZ, Xu F, Zheng M, Man XY.
Nat Commun. 2025 Oct 13;16(1):9084. doi: 10.1038/s41467-025-64106-6.
PMID: 41083457
10.角质形成细胞特异性H4K12乳酸化驱动小鼠银屑病非经典IL-17依赖信号通路
Keratinocyte-specific H4K12 lactylation drives a non-canonical IL-17-dependent signaling in psoriasis progression in mice.
Shen X, Qiao W, Yan W, Xie H, Zhang C, Sun Y, Luo Q, Xu Q.
Nat Commun. 2025 Sep 30;16(1):8639. doi: 10.1038/s41467-025-63791-7.
PMID: 41027887
11.5-羟色胺2A受体通过抑制单核细胞来源朗格汉斯细胞IL-23分泌缓解银屑病炎症
Serotonin 2A receptor attenuates psoriatic inflammation by suppressing IL-23 secretion in monocyte-derived Langerhans cells.
Tan YF, Yeh CY, Hsu SY, Lu CH, Tsai CH, Chiang PC, Weng HJ, Tsai TF, Lee YL.
Nat Commun. 2025 Sep 29;16(1):8544. doi: 10.1038/s41467-025-63971-5.
PMID: 41022781
12.CD137L通过HLTF调控促进黑色素瘤免疫监视
CD137L promotes immune surveillance in melanoma via HLTF regulation.
Liang L, Zhu L, Li X, Zhou W, Zhang Y, Hung MC, Zhang G, Chen Y, Kuang X, Su J, Liu J, Chen X, Liu H.
Nat Commun. 2025 Sep 26;16(1):8478. doi: 10.1038/s41467-025-63338-w.
PMID: 41006211
13.人皮肤成纤维细胞单细胞及空间基因组图谱揭示跨组织的共享疾病相关成纤维细胞亚型
A single-cell and spatial genomics atlas of human skin fibroblasts reveals shared disease-related fibroblast subtypes across tissues.
Steele L, Olabi B, Roberts K, Mazin PV, Koplev S, Tudor C, Rumney B, Admane C, Jiang T, Correa-Gallegos D, Chakala KP, Binkevich A, Gopee NH, Predeus A, Prete M, Winheim E, Annusver K, Forsthuber A, Francis L, Frech S, Ganier C, Layton T, Liu Y, Yuan H, Gudjonsson JE, Lichtenberger BM, Mahil S, Nanchahal J, O'Toole EA, Plikus MV, Rinkevich Y, Rognoni E, Smith CH, Teichmann SA, Kasper M, Foster AR, Lotfollahi M, Haniffa M.
Nat Immunol. 2025 Oct;26(10):1807-1820. doi: 10.1038/s41590-025-02267-8. Epub 2025 Sep 24.
PMID: 40993240
14.CCR7(+)树突状细胞同时表达IL-23A与IL-12B可能促进银屑病复发
CCR7(+) dendritic cells expressing both IL-23A and IL-12B potentially contribute to psoriasis relapse.
Sun Y, Lou F, Cai X, Wang Z, Yang X, Sun L, Xu Z, Deng S, Wu Z, Liu Z, Shi YL, Ginhoux F, Wang H.
Nat Commun. 2025 Aug 15;16(1):7581. doi: 10.1038/s41467-025-62874-9.
PMID: 40817122
15.体外微生态模型复制人皮肤微生物群相互作用
Microecology in vitro model replicates the human skin microbiome interactions.
Wang P, Li H, Zhang X, Wang X, Sun W, Zhang X, Chi B, Go Y, Chan XHF, Wu J, Huang Q.
Nat Commun. 2025 Mar 31;16(1):3085. doi: 10.1038/s41467-025-58377-2.
PMID: 40164644
16.MCL-1保护激活的毛囊干细胞以实现成人毛发再生
MCL‑1 safeguards activated hair follicle stem cells to enable adult hair regeneration.
Chin HS, Cheng J, Hsu SH, Lum GG, Zaldivia MT, Nelameham S, Guo F, Mallavarapu K, Jackling FC, Yang J, Tan JSL, Sampath P, Barker N, Smyth GK, Lindeman GJ, Strasser A, Visvader JE, Chen Y, Chen T, Fu NY.
Nat Commun. 2025 Mar 22;16(1):2829. doi: 10.1038/s41467-025-58150-5.
PMID: 40121237
17.基质产生中性粒细胞聚集并保护皮肤
Matrix-producing neutrophils populate and shield the skin.
Vicanolo T, Özcan A, Li JL, Huerta-López C, Ballesteros I, Rubio-Ponce A, Dumitru AC, Nicolás-Ávila JÁ, Molina-Moreno M, Reyes-Gutierrez P, Johnston AD, Martone C, Greto E, Quílez-Alvarez A, Calvo E, Bonzon-Kulichenko E, Álvarez-Velez R, Chooi MY, Kwok I, González-Bermúdez B, Malleret B, Espinosa FM, Zhang M, Wang YL, Sun D, Zhen Chong S, El-Armouche A, Kim KK, Udalova IA, Greco V, Garcia R, Vázquez J, Dopazo A, Plaza GR, Alegre-Cebollada J, Uderhardt S, Ng LG, Hidalgo A.
Nature. 2025 May;641(8063):740-748. doi: 10.1038/s41586-025-08741-5. Epub 2025 Mar 19.
PMID: 40108463
18.植物精油靶向TRPV3实现皮肤更新及其结构作用机制
Plant essential oil targets TRPV3 for skin renewal and structural mechanism of action.
Li Y, Lu X, Cheng X, Xia K, Hu J, Wang P, Pang P, Gao B, Sun D, Zhang Z, Li D, Deng Z, Tian C, Xie C, Yao J.
Nat Commun. 2025 Mar 19;16(1):2728. doi: 10.1038/s41467-025-58033-9.
PMID: 40108208
19.用于皮肤健康的表皮丝氨酸感应系统
An epidermal serine sensing system for skin healthcare.
Yuan Y, Zhong B, Qin X, Xu H, Li Z, Li L, Wang X, Zhang W, Lou Z, Fan Y, Wang L.
Nat Commun. 2025 Mar 18;16(1):2681. doi: 10.1038/s41467-025-58147-0.
PMID: 40102486
20.重编程有氧代谢减轻小鼠坏死性皮肤感染中链球菌造成的组织损伤
Reprogramming aerobic metabolism mitigates Streptococcus pyogenes tissue damage in a mouse necrotizing skin infection model.
Xu W, Bradstreet TR, Zou Z, Hickerson S, Zhou Y, He H, Edelson BT, Caparon MG.
Nat Commun. 2025 Mar 15;16(1):2559. doi: 10.1038/s41467-025-57348-x.
PMID: 40089471
21.基于皮肤类器官的感染平台发现手足口病特异性抑制剂
A skin organoid-based infection platform identifies an inhibitor specific for HFMD.
Li J, Ma J, Cao R, Zhang Q, Li M, Wang W, Wang Y, Li W, Zhu Y, Leng L.
Nat Commun. 2025 Mar 13;16(1):2513. doi: 10.1038/s41467-025-57610-2.
PMID: 40082449
22.PD-L1琥珀酰化改变影响黑色素瘤抗肿瘤免疫反应
Alterations in PD-L1 succinylation shape anti-tumor immune responses in melanoma.
Liang L, Kuang X, He Y, Zhu L, Lau P, Li X, Luo D, Gong L, Zhou W, Zhang F, Liang X, Li Z, Hu B, Liu D, Ding T, Li H, Zhao S, Su J, Hung MC, Liu J, Liu H, Chen X.
Nat Genet. 2025 Mar;57(3):680-693. doi: 10.1038/s41588-025-02077-6. Epub 2025 Mar 11.
PMID: 40069506
23.淋巴源性氧甾醇促进黑色素瘤抗肿瘤免疫及免疫治疗反应
Lymphatic-derived oxysterols promote anti-tumor immunity and response to immunotherapy in melanoma.
Sun M, Garnier L, Chevalier R, Roumain M, Wang C, Angelillo J, Montorfani J, Pick R, Brighouse D, Fournier N, Tarussio D, Tissot S, Lobaccaro JM, Petrova TV, Jandus C, Speiser DE, Kopf M, Pot C, Scheiermann C, Homicsko K, Muccioli GG, Garg AD, Hugues S.
Nat Commun. 2025 Jan 31;16(1):1217. doi: 10.1038/s41467-025-55969-w.
PMID: 39890772
24.CD133(+)PD-L1(+)癌细胞赋予黑色素瘤对工程化巨噬细胞过继疗法的耐受性
CD133(+)PD-L1(+) cancer cells confer resistance to adoptively transferred engineered macrophage-based therapy in melanoma.
Xu J, Li Z, Tong Q, Zhang S, Fang J, Wu A, Wei G, Zhang C, Yu S, Zheng B, Lin H, Liao X, Xiao Z, Lu W.
Nat Commun. 2025 Jan 21;16(1):895. doi: 10.1038/s41467-025-55876-0.
PMID: 39837811
25.清除高p21表达的衰老细胞加速皮肤伤口愈合
Clearance of p21 highly expressing senescent cells accelerates cutaneous wound healing.
Gasek NS, Yan P, Zhu J, Purushothaman KR, Kim T, Wang L, Wang B, Flynn WF, Sun M, Guo C, Huggins B, Sharafieh R, Zhou Y, Parizek V, Tchkonia T, Kirkland JL, Wyles SP, Xu M.
Nat Aging. 2025 Jan;5(1):21-27. doi: 10.1038/s43587-024-00755-4.
PMID: 39537987
2025年度Cell及子刊合集
（最新IF：Cell, 42.5；Cell Reports, 6.9）
1.成纤维细胞生物电信号驱动毛发生长
Fibroblast bioelectric signaling drives hair growth.
Chen D, Yu Z, Wu W, Du Y, Du Q, Huang H, Li Y, Xuan T, Liang YC, Liu Y, Wang Z, Su R, Zhao Y, Li Q, Luo M, Wang F, Li J, Chuong CM, Lin Z, Chen T.
Cell. 2025 Sep 18;188(19):5175-5193.e21. doi: 10.1016/j.cell.2025.07.035. Epub 2025 Aug 15.
PMID: 40818454
2.皮肤中的机械抗性机制适应陆生运动
A mechano-resistance mechanism in skin adapts to terrestrial locomotion.
Di R, Du Q, Xie Y, Lu Y, Gao W, Zhang L, Qi X, Fan Y, Li J, Wang F, Chen S, Chen T.
Cell. 2025 Oct 16;188(21):5797-5808.e16. doi: 10.1016/j.cell.2025.07.012. Epub 2025 Aug 4.
PMID: 40763735
3.来源于iPSC的CD19/BCMA CAR-NK细胞疗法用于系统性硬化患者
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis.
Wang X, Zhang Y, Jin Y, Dai L, Yue Y, Hu J, Liu X, Pang K, Ye S, Chen Y, Ye W, Shi X, Ma X, Guo L, Liu Y, Ta N, Zhu X, Lin L, Wang J, Yan R, Wang P, Song X, Zhou Y, Zhou L, Wang Q, Guan T, Li T, Zhou L, Pan W, He Y, Wu X, Xu Y, Yang L, Xu H.
Cell. 2025 Aug 7;188(16):4225-4238.e12. doi: 10.1016/j.cell.2025.05.038. Epub 2025 Jun 24.
PMID: 40562027
4.大麻素CB2受体通过调控脊髓小胶质细胞活化及突触传递控制慢性瘙痒
Cannabinoid CB2 receptor controls chronic itch by regulating spinal microglial activation and synaptic transmission.
Xu K, Liu X, Zeng Q, Liu Y, Shan L, Ji L, Wu Y, Wu J, Chen Y, Li Y, Huang S, Jiang C, Hong X, Wu C, Wang Z.
Cell Rep. 2025 Apr 22;44(4):115559. doi: 10.1016/j.celrep.2025.115559. Epub 2025 Apr 11.
PMID: 40222011
说明：以上列表按论文出版时间由近及远排列（时间倒序）。凡有中国单位（含港澳台）作者参与的论文均计入。
完
免责声明
本文内容基于已公开的临床研究数据、学术文献及行业信息整理，仅用于医学与行业信息交流，不构成任何具体的诊疗建议或用药推荐。文中提及的药物或治疗手段，部分仍处于临床研究阶段或尚未获批，其安全性和有效性需以监管部门最终批准及正式说明书为准。患者如有相关疾病或症状，请在专业皮肤科医生指导下进行规范诊疗，切勿依据本文信息自行判断或用药。
版权声明
本文由“肤界”编辑部负责翻译、撰写或约稿，内容用于医学学术交流与信息分享，不代表本平台立场。文章内容不能替代专业医疗判断，平台不对内容的适时性及所引用资料的完整性、准确性作出保证。
如涉及内容差错或版权问题，请联系我们及时更正或删除。
未经授权，禁止转载。转载或合作请联系：BJDCN@med-think.com
临床研究
2025-12-28
点击蓝字
关注我们
导读
肝移植是终末期肝病，特别是肝细胞癌（HCC）患者的根治性手段。由于供肝来源持续短缺，临床常采用米兰标准、加州大学旧金山分校（UCSF）标准和杭州标准等严格筛选标准来评估HCC患者是否适宜接受移植。尽管桥接治疗或降期治疗为部分患者创造了移植条件，但多数HCC患者确诊时已处于中晚期，并不符合直接移植指征。
近年来，以PD-1、PD-L1及CTLA-4为靶点的免疫检查点抑制剂（ICIs）已成为晚期HCC重要的全身治疗方式。ICIs不仅提高了治疗应答率，也使更多患者得以在移植前实现成功降期，进而获得移植机会。然而，移植前暴露于ICIs也与移植物排斥风险的显著升高相关，据报道其排斥反应发生率常超过20%，且此类排斥多由T细胞介导，与传统排斥相比往往程度更重、治疗更困难，并伴有更高的移植物失功率。目前，尽管已对ICIs洗脱期、患者年龄及ICIs类型等因素与排斥风险的相关性进行了探讨，但其预测价值仍有限，临床上尚未就最佳管理策略达成共识。值得注意的是，免疫相关不良事件（irAEs）作为ICIs治疗期间全身免疫激活的常见并发症，也可能与移植后排斥反应相关，irAEs以多系统炎症反应为特征，且可在停药后持续存在。从机制上看，irAEs与全身免疫过度激活相关，因而可能形成有利于移植物排斥的免疫微环境。
基于以上背景，研究人员展开了一项全国性多中心回顾性队列研究，旨在探讨肝移植前接受ICIs治疗的HCC患者中，irAEs与移植后移植物排斥风险之间的关联。同时，研究试图识别影响排斥反应的独立风险因素，并构建相应的预测模型。
研究亮点抢先看
irAEs是肝移植后排斥反应的最强预测因子（OR=9.170，P<0.001），其他独立风险因素包括受者年龄<40岁和洗脱期<30天。
基于上述因素构建的预测模型曲线下面积（AUC）达0.788，具有良好的区分能力。
此外，发生irAEs的患者外周血CD8+T细胞数量增加，IFN-α和TNF-α水平升高，表明免疫激活与排斥风险密切相关。
研究一览
研究方法
本研究为一项全国多中心回顾性队列研究，旨在探索肝移植前接受ICIs治疗的HCC患者发生移植物排斥反应的风险因素。
研究纳入2018年1月至2024年6月期间在七家高手术量中心接受至少一周期ICIs桥接或降期治疗、经组织学确诊为肝细胞癌、年龄18~75岁的成年患者，排除了活动性自身免疫病、多器官移植、肝功能严重不全及存在肝外转移等情况的病例。
研究通过电子病历或病例报告表，收集包括人口统计学特征、肝病病因、是否存在肝硬化、ECOG体能状态评分、实验室数据、肿瘤特征、供者年龄、移植物类型、冷缺血时间、HCC治疗方案、治疗反应、免疫相关不良事件及患者生存情况等信息。
主要研究终点为移植物排斥反应（依据Banff标准诊断，其中61.1%经活检证实）和患者生存情况；次要终点包括肿瘤治疗反应和irAEs。统计分析采用SPSS、R等软件，通过单因素与多因素逻辑回归识别风险因素，并使用竞争风险模型校正死亡事件的干扰。预测模型效能通过ROC曲线评估，生存分析采用Kaplan-Meier法，组间免疫指标比较使用经Bonferroni校正的非参数检验。研究旨在为临床提供ICIs在肝移植围手术期应用的风险评估与管理依据。
研究结果
研究共纳入209例在肝移植前接受过ICIs治疗的HCC患者。患者中位年龄为52.3岁，绝大多数为男性（94.3%）。根据巴塞罗那临床肝癌分期标准，多数患者处于C期（45.4%），其次为B期（27.8%）和0/A期（26.8%）。绝大多数患者伴有肝硬化（89.5%）。不符合米兰标准和加州大学旧金山分校标准的患者分别占全部病例的80.9%和74.6%。
多数患者（69.4%）接受了包含ICIs、靶向治疗及局部区域治疗的三联方案，23.4%的患者接受了双联方案。免疫治疗以PD-1抑制剂为主（88.7%），其中卡瑞利珠单抗（23.9%）与信迪利单抗（23.9%）最为常用。患者接受ICIs治疗的中位周期数为3.0，中位洗脱期为66天，若按ICIs药物半衰期折算则为3.1个半衰期。总体而言，HCC治疗的客观缓解率为58.4%，疾病控制率达86.1%。
免疫相关不良事件发生情况
共44例（21.1%）患者记录到irAEs（表1）。多数irAEs为低级别，其中38例（86.4%）为1~2级，6例（13.6%）为3~4级。从累及范围看，单部位irAEs见于36例（81.8%）患者，而多部位irAEs见于8例（18.2%）患者。在单部位irAEs中，皮肤事件最为常见，共14例（占irAEs患者总数的31.8%）。此外，有13例（29.5%）患者因irAEs需接受糖皮质激素治疗，6例（13.6%）患者因此终止治疗。
表1. irAEs发生率
排斥反应及其风险因素
在209例患者中，36例（17.2%）出现同种异体移植物排斥反应，中位发生时间为肝移植后10天。排斥组与非排斥组在患者基本特征、治疗策略及应答情况方面均无显著差异。值得注意的是，排斥组中洗脱期＜30天的患者比例更高（33.3% vs. 15.0%，P=0.071），且irAEs发生率显著更高（58.3% vs. 13.3%，P<0.001）。排斥组患者1年生存率显著更低（HR=3.561，95%CI：1.010~12.550，P=0.048），但该差异在3年时未达到显著性（HR=2.098，95%CI：0.745~5.908，P=0.161）（图1）。
图1. 排斥组与非排斥组总体生存率的Kaplan-Meier曲线比较。（A）1年生存曲线；（B）3年生存曲线
采用逻辑回归分析探讨移植排斥的潜在风险因素（表2）。结果显示，供体年龄、冷缺血时间（CIT）、移植物类型、ICIs药物类型、ICIs治疗周期、治疗反应及基于ICIs特定半衰期计算的洗脱期等因素，均与排斥反应无显著相关性。单因素分析显示，受者年龄、洗脱期＜30天及irAEs为潜在危险因素（P<0.05）。多因素分析进一步证实三者均为排斥反应的独立风险因素，其中irAEs是排斥反应的最强预测因子，可使排斥风险独立增加超过九倍（OR=9.170，P<0.001，AUC达0.725）。其他独立危险因素包括受者年龄＜40岁（OR=3.028，P=0.049，AUC=0.568）以及ICIs洗脱期＜30天（OR=3.071，P=0.018，AUC=0.592）。竞争风险分析亦得到相似结果。
表2. 同种异体移植排斥反应风险因素的单因素与多因素分析
基于上述三个独立风险因素构建预测模型，其AUC（0.788）显著高于任一单一风险因素（均P<0.05）。依据该模型可将患者分为高风险组与低风险组，其预测排斥概率分别为50.0%与8.0%（图2）。
图2. 移植排斥反应的预测模型。（A）各独立风险因素与预测模型的ROC曲线。（B）预测模型与各独立风险因素所对应的排斥概率比较柱状图。AUC：曲线下面积；irAEs：免疫相关不良事件；ROC：患者工作特征曲线。
irAEs与宿主免疫过度激活相关
为探讨irAEs相关的免疫表型，研究前瞻性收集了23例等候肝移植的HCC患者在三个时间点（治疗前、治疗1周期后、治疗≥3周期后）的外周血样本。其中7例出现irAEs，最终纳入7例irAEs患者与7例匹配的非irAEs患者进行分析。通过比较发现，在治疗后时间点，irAE组患者相较于非irAEs组的CD8+T细胞数量显著增加，且IFN-α与TNF-α水平明显升高（图3A~F）。其余炎症细胞因子则未见显著差异。
图3. irAEs组与非irAEs组的免疫表型及分子特征对比。(A)免疫细胞亚群绝对计数的热图；(B)CD8+T细胞绝对计数的散点-柱状图；(C)CD8+T细胞相对计数的散点-柱状图；(D)炎症因子水平的热图；(E)TNF-α水平的散点-柱状图；(F)IFN-α水平的散点-柱状图；(G)外周免疫细胞差异表达基因的REACTOME通路分析；(H)使用METASCAPE对差异表达基因进行功能富集分析。
此外，研究对两组患者的外周免疫细胞转录谱进行了分析。结果显示，在irAEs组与非irAEs组之间共鉴定出105个差异表达基因。REACTOME通路分析显示，这些差异表达基因在免疫系统通路中显著富集（错误发现率，FDR<0.001），而在其他通路中未观察到明显富集（图3G）进一步使用METASCAPE对其中48个免疫相关基因的分析表明，这些基因主要富集于细胞因子反应、炎症反应及免疫效应过程调控等通路（图3H）。典型的分子变化包括CD274（PD-L1）、IL1RN和LY6E的下调，以及CD40LG和CEACAM1的上调，这些改变共同提示，与非irAEs组相比，irAEs组具有更强的促炎活性和更高的T细胞活化水平。
研究结论
本研究证实，在肝移植前接受ICIs治疗的HCC患者中，irAEs是同种异体移植物排斥反应的重要预测因子，其机制可能与机体免疫过度激活相关。所构建的预测模型或有助于对高排斥风险患者进行分层识别。
讨论
本研究证实，在接受ICIs治疗的HCC肝移植患者中，irAEs的发生是术后移植物排斥反应的强效预测因子。数据显示，发生irAEs的患者排斥率高达58.3%，远高于未发生者（13.3%），且irAEs可使排斥风险独立增加超过九倍。此外，研究还识别出另两项独立危险因素：年龄＜40岁的受者排斥风险增加约3倍，提示年轻患者免疫系统反应性更强，更易发生排斥；而ICI停药至移植的洗脱期＜30天亦使风险增加3.1倍，这凸显了保证足够洗脱期对降低术后排斥的重要性。基于上述因素构建的预测模型有效区分了排斥风险（AUC=0.788），有望为临床评估提供量化工具。
然而研究同样存在一定局限性，包括样本量尤其是严重irAEs病例数有限，限制了分层分析及机制探索的稳健性；队列存在明显性别失衡，影响基于性别的深入分析；亦未对关键免疫参数进行系统监测。因此，未来需在更大规模、更均衡的移植人群中开展纵向免疫学研究加以验证和拓展。
尽管如此，本研究明确提示irAEs可作为预测移植后排斥风险的免疫学生物标志物。在临床实践中，这意味着发生irAEs的患者在肝移植前可能需要更长的洗脱期、更严密的围术期免疫监测以及更审慎的免疫抑制方案调整。这些发现为改善移植前风险分层提供了依据，并支持采用免疫监测指导的个体化策略，以优化移植时机并降低移植物排斥风险。
参考文献Fang J, et al. Gut. 2025 Nov 4:gutjnl-2025-336719.
（来源：肿瘤瞭望消化时讯）
声 明
凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。
2025-12-25
点击蓝字
关注我们
2025年终成果汇总
THE LATEST RESULTS
2025年已渐近尾声，在这一年里，徐Lab凭借着不懈的努力与执着追求，在科研领域持续深耕，不断收获累累硕果，书写着属于自己的精彩篇章。
01
论文发表成果斐然
在课题组组长的高瞻远瞩与精心引领下，全体学生和工作人员齐心协力、奋勇拼搏，共同营造出积极向上、勇于创新的科研氛围。本年度，团队在学术期刊发表方面成绩卓著，已在正刊及子刊级累计发表论文达27余篇。这一数字不仅是对课题组过去一年辛勤付出的有力肯定，更是其在科研道路上不断攀登高峰的有力见证。
02
重大突破再谱新篇
值得一提的是，继在《Nature》（2024）上首次揭示NET同源二聚化机制及抗抑郁药物识别机制后，2025年10月24日，临港实验室蒋轶研究员团队联合中国科学院上海药物研究所徐华强研究员、杨德华研究员团队，以及临港实验室王震研究员团队，在《Cell》上在线发表了题为“Unveiling conformation-selectivity regulation of the norepinephrine transporter”的研究论文。Cell | 蒋轶/徐华强/杨德华/王震团队提出去甲肾上腺素转运体构象选择性变构调控模型，为新一代抗抑郁药开发提供了新思路!
除了这一重大突破，课题组还有26篇子刊级文章发表，研究范围从G蛋白偶联受体解析到人工智能驱动下的产出，涵盖了多个前沿领域，充分展示了课题组广泛的科研视野和强大的科研实力。
03
黄金法则：高效科研，创新驱动
揭秘徐华强课题组高效科研背后的“黄金法则”，犹如揭开一层神秘的面纱，让我们看到了其成功的秘诀。
结构决定功能，解析驱动创新
G蛋白偶联受体（GPCR）是重要的药物靶点，其结构解析长期依赖传统X射线晶体学方法，存在诸多限制。冷冻电镜技术的突破使得科学家能在近生理状态下解析GPCR与其配体及G蛋白的复合物结构，极大地推动了相关功能机制的研究。基于结构的药物设计（SBDD）能够帮助开发更具选择性、副作用更小的药物分子。此外，针对GPCR信号通路的特异性调控，设计偏向性激动剂或拮抗剂，也为疾病个性化治疗提供了新方向。
机制深度解析，靶向精准干预
去甲肾上腺素转运体（NET）等神经递质转运体是抗抑郁药、兴奋剂等多种精神神经疾病药物的关键靶点。在对其研究中，课题组遵循多层次机制剖析的法则。在原子水平上，结合冷冻电镜和分子动力学模拟，如同显微镜下的精细观察，揭示底物识别、结合和转运的原子细节，让我们对 NET 的工作机制有了更深入的了解。研究转运体从向外开放到向内开放的完整构象变化周期，如同追踪一场精彩的舞蹈表演，了解其在不同状态下的变化规律，构建起一个完整的调控网络，为精准干预提供了理论依据。
数据智能驱动，颠覆传统范式
在当今科技飞速发展的时代，人工智能为科研带来了新的机遇和挑战。AlphaFold 革命准确预测蛋白质结构，如同拥有一本神奇的预言书，极大加速了靶点识别和验证阶段，节省了大量的时间和资源。生成式 AI 模型能够设计具有理想理化性质和结合特的全新分子结构，为药物研发提供了更多的可能性。强化学习优化通过循环的“设计 - 合成 - 测试”反馈，如同一个智能的优化大师，快速优化先导化合物，提高药物研发的效率和质量。
04
文化传承：火炬传递，突破无限
随着科研工作的深入推进，从基础研究到结构解析，再到临床新药验证，一代代的科研人如同接力赛中的运动员，举起手中的火炬进行“代帮式”的传递。这种传承不仅传递了知识和技能，更传递了科研的精神和理念，使得徐Lab喜报频传，形成了课题组隐形的文化力量。文章的发表不应该仅仅是数字的积累，更是团队科研理念与方法论的胜利。在这种理念的指引下，课题组不断实现“从0到1”的科研突破，为推动科研事业的发展做出了重要贡献。
2025年即将结束，2026年的脚步正徐徐走来，祝愿徐Lab以及上海市高峰电镜中心继往开来，再攀高峰！
06
2025年度徐华强课题组已发表论文汇总
1： Meng X, Li Y, Xu J, Wu K, Hu W, Wu C, Xu HE, Xu Y. Structural insights into the activation of the human prostaglandin E2 receptor EP1 subtype by prostaglandin E2. Proc Natl Acad Sci USA. 2025May20;122(20):e2423840122. doi: 10.1073/pnas.2423840122. Epub 2025May14. PMID: 40366695; PMCID: PMC12107139.
2: Wang RL, Sun J, Liu H, Guo SM, Zhang Y, Hu W, Wang J, Liu H, Zhuang YW, Jiang Y, Xie X, Xu HE, Wang Y. Molecular recognition of two approved drugs Macimorelin and Anamorelin by the growth hormone secretagogue receptor. Acta Pharmacol Sin. 2025 Nov; 46(11): 2998-3008. doi: 10.1038/s41401-025-01606-7. Epub 2025 Jun 20.PMID: 40542284; PMCID: PMC12552520.
3: He XH, Li JR, Xu J, Shan H, Shen SY, Gao SH, Xu HE. AI-driven antibody design with generative diffusion models: current insights and future directions. Acta Pharmacol Sin. 2025 Mar;46(3):565-574. doi: 10.1038/s41401-024-01380-y. Epub 2024 Sep 30. PMID: 39349764; PMCID: PMC11845702.
4: Gu YM, Yuan QN, Li X, He Q, Xu HE, Zhao LH. Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors. Acta Pharmacol Sin. 2025 Aug 22. doi: 10.1038/s41401-025-01635-2.Epub ahead of print. PMID: 40847076.
5: Jiang M, Xu Y, Luan X, Wu K, Li Z, Xu HE, Zhang S, Jiang Y, Yin W. Structural basis of the cysteinyl leukotriene receptor type 2 activation by LTD4. Proc Natl Acad Sci U S A. 2025 Apr 15;122(15):e2417148122. doi: 10.1073/pnas.2417148122.Epub 2025 Apr 7. Erratum in: Proc Natl Acad Sci U S A. 2025 Jun 24;122(25):e2512181122. doi: 10.1073/pnas.2512181122. PMID: 40193607; PMCID:PMC12012480.
6: Xia R, Yuan Q, Wang N, Hou L, Abe J, Song J, Ito Y, Xu HE, He Y. Structural insight into GPR55 ligand recognition and G-protein coupling. Cell Res. 2025 Jan;35(1):76-79. doi: 10.1038/s41422-024-01044-w. Epub 2024 Oct 31. PMID:39482404; PMCID: PMC11701112.
7: Shen S, He X, Liu H, Hu W, Xu HE, Duan J. Cryo-EM structures of GnRHR: Foundations for next-generation therapeutics. Proc Natl Acad Sci U S A. 2025 Jun 24;122(25):e2500112122. doi: 10.1073/pnas.2500112122. Epub 2025 Jun 16. PMID:40523184; PMCID: PMC12207466.
8: Zhang H, Zhang T, Wang D, Dai A, Mao J, Chen Q, Du T, Lu X, Hao Y, Zhang C,Yin YL, Hu W, Pan B, Jin S, Jiang M, Si Y, Yuan Q, Wang MW, Zheng M, Wang Z,Yang D, Xu HE, Jiang Y. Unveiling conformation-selective regulation of the norepinephrine transporter. Cell. 2025 Nov 26;188(24):6861-6872.e14. doi: 10.1016/j.cell.2025.10.002. Epub 2025 Oct 24. PMID: 41138730.
9: Xu J, Wu Y, Xu Y, Li Y, He X, Zhang H, Wang JJ, Hou J, Li J, Hu W, Wu K, Yuan Q, Wu C, Xu HE. Molecular basis for ligand recognition and receptor activation of the prostaglandin D2 receptor DP1. Proc Natl Acad Sci U S A. 2025 Jun 3;122(22):e2501902122. doi: 10.1073/pnas.2501902122. Epub 2025 May 29. PMID:40440061; PMCID: PMC12146711.
10: You C, Jiang M, Gao T, Zhu Z, He X, Xu Y, Gao Y, Jiang Y, Xu HE. Decoding the structural basis of ligand recognition and biased signaling in the motilin receptor. Cell Rep. 2025 Mar 25;44(3):115329. doi: 10.1016/j.celrep.2025.115329.Epub 2025 Feb 22. PMID: 39987561.
11: You C, Guo S, Zhang T, He X, Gao T, Xin W, Zhu Z, Lu Y, Xu Y, Li Z, Zhang Y, Cheng X, Jiang Y, Xie X, Xu HE. Molecular mechanism of pH sensing and activation in GPR4 reveals proton-mediated GPCR signaling.Cell Discov. 2025 Jun 25;11(1):59.doi: 10.1038/s41421-025-00807-y. PMID: 40555728; PMCID:PMC12187918.
12: Sun D, Li X, Yuan Q, Wang Y, Shi P, Zhang H, Wang T, Sun W, Ling S, Liu Y, Lai J, Xie W, Yin W, Liu L, Xu HE, Tian C. Molecular mechanism of the arrestin-biased agonism of neurotensin receptor 1 by an intracellular allosteric modulator. Cell Res. 2025 Apr;35(4):284-295. doi:10.1038/s41422-025-01095-7.Epub 2025 Mar 21. PMID: 40118988; PMCID: PMC11958688.
13: Wu C, Zhang C, Jin S, Wang JJ, Dai A, Xu J, Zhang H, Yang X, He X, Yuan Q, Hu W, Xu Y, Wang M, Jiang Y, Yang D, Xu HE. Molecular mechanisms of urate transport by the native human URAT1 and its inhibition by anti-gout drugs. Cell Discov. 2025 Apr 1;11(1):33. doi: 10.1038/s41421-025-00779-z. PMID: 40169562;PMCID: PMC11962085.
14: Zhang H, Cui N, Ma X, Xu HE. Structural basis of augmenting taurine uptake by the taurine transporter in alleviating cellular senescence. Cell Res. 2025 May;35(5):385-388. doi: 10.1038/s41422-025-01090-y. Epub 2025 Mar 20. PMID:40108449; PMCID: PMC12012219.
15: Zhu X, Ping M, Liu H, Yu T, Jiang Z, Liu Z, Li C, Hou X, Chu Q, Li S, Mao C, Luo T, Kang C, Wang F, Yang C, Tang M, Jiang Z, Gao Z, Liu H, Xu HE, Tang B, Cheng X, Yin W, Zhou Y, Li P. Structural insights into the activation of TMEM175 by small molecule. Neuron. 2025 Nov 5;113(21):3567-3581.e9. doi:10.1016/j.neuron.2025.07.029. Epub 2025 Aug 26. PMID: 40865534.
16: He XH, Li JR, Shen SY, Xu HE. AlphaFold3 versus experimental structures: assessment of the accuracy in ligand-bound G protein-coupled receptors. Acta Pharmacol Sin. 2025 Apr;46(4):1111-1122. doi: 10.1038/s41401-024-01429-y. Epub 2024 Dec 6. PMID: 39643640; PMCID: PMC11950431.
17: Zhang T, Liu H, You C, Zhang Y, Xu Y, Pan B, Wu C, Jin S, Yin YL, Wu K, Chen Y, Sun H, Si Y, Tan Y, Yin W, Xu HE, Guo D, Jiang Y. Structural insights into antagonist recognition by the vasopressin V2 receptor. Nat Commun. 2025 Nov 4;16(1):9734. doi: 10.1038/s41467-025-64735-x. PMID: 41188237; PMCID:PMC12586607.
18: Li X, Zhang H, Hu W, Wu K, Li S, Jin S, Yin Y, Yuan Q, Xu HE, Pan B, Jiang Y. Structural basis of peptide recognition and modulation for neuropeptide FF receptors. Cell Rep. 2025 Sep 23;44(9):116160. doi:10.1016/j.celrep.2025.116160. Epub 2025 Aug 19. PMID: 40839429.
19: Luo P, Xin W, Guo S, Li X, Zhang Q, Xu Y, He X, Wang Y, Fan W, Yuan Q, Wu K, Hu W, Zhuang Y, Xu HE, Xie X. Structural insights into the agonist activity of the nonpeptide modulator JR14a on C3aR. Cell Discov. 2025 Jan 10;11(1):7. doi:10.1038/s41421-024-00765-x. PMID: 39788969; PMCID: PMC11718183.
20: Li J, Li C, Zhou Q, Han W, Fang M, Xu Y, Mai Y, Zhang Y, Cui J, Xu HE, Zhang Y, Yin W, Wang MW. Divergent activation patterns of BRS3 revealed by two Chinese herb-derived agonists. Acta Pharm Sin B. 2025 Oct;15(10):5231-5243. doi:10.1016/j.apsb.2025.06.025. Epub 2025 Jun 30. PMID: 41132856; PMCID:PMC12541581.
21: Cao Y, Zhang C, Yuan Q, Zhao F, Liu Q, Wu K, Hu W, He J, Li H, Xu HE, Yang D, Duan J. Mechanisms of chemokine recognition and receptor activation of chemokine receptor CCR7. Cell Rep. 2025 Nov 25;44(11):116582. doi:10.1016/j.celrep.2025.116582. Epub 2025 Nov 17. PMID: 41252250.
22: Jin SS, Zhang H, Yan JH, Wu CR, Cai XQ, Wu K, Wang MW, Xu HE, Yang DH, Jiang Y. Decoding ligand recognition and constitutive activation of histamine H3 and H4 receptors. Acta Pharmacol Sin. 2025 Aug 28. doi: 10.1038/s41401-025-01633-4. Epub ahead of print. PMID: 40877594.
23: Gao T, You C, Cao Y, Xu X, Yuan Q, Shen S, Xu HE, Duan J. Structural insights into hormone recognition and G-protein coupling of the urotensin-II receptor. J Biol Chem. 2025 Nov;301(11):110794. doi: 10.1016/j.jbc.2025.110794.Epub 2025 Oct 6. PMID: 41062066; PMCID: PMC12630362.
24: Wu Y, Zhang H, Xu J, Wu K, Hu W, He X, Wang G, Wu C, Xu HE. Structural insights into selective and dual antagonism of EP2 and EP4 prostaglandin receptors. EMBO J. 2025 Dec;44(23):7242-7262. doi: 10.1038/s44318-025-00611-0. Epub 2025 Oct 29. PMID: 41162752; PMCID: PMC12669672.
25: Shen SY, Li JR, Wang YS, Li SN, Xu HE, He XH. An update for AlphaFold3 versus experimental structures: assessing the precision of small molecule binding in GPCRs. Acta Pharmacol Sin. 2025 Dec;46(12):3355-3364. doi:10.1038/s41401-025-01617-4. Epub 2025 Jul 9. PMID: 40634710; PMCID: PMC12644867.
26： Li Y, Xing Z, Hu W, Wu K, Xu HE, Zhao LH. Structural insights into nonpeptide antagonist inhibition of somatostatin receptor subtype 5. Proc Natl Acad Sci U S A. 2025 Dec 23;122(51):e2522515122. doi: 10.1073/pnas.2522515122. Epub 2025 Dec 19. PMID: 41417603.
27：Li S, Yuan Q, Wu W, Chen Z, Chen D, Shan H, Chu Q, Hu W, Wu K, Liu T, Zhu Y, Hou L, Zhou J, Duan J, Duan J, Xu HE, Ma H.Structural Pharmacology of Bufotenine Derivatives in Activating the 5-HT1A Receptor for Therapeutic Potential in Depression and Anxiety. Research. 23 Dec 2025 Vol 8 Article ID: 0987
07
博后招聘
我们长期招药学、化学、生物学、结构生物学、生物物理学、计算机科学等相关专业的博后，博后工作地址可以在上海、广州、深圳和中山等多家单位招聘启事｜广医徐有伟团队招聘博后，年薪23-30万+绩效奖励6-100万招聘启事｜中山药创院尹万超课题组诚聘博士后。
----
文字图片 ｜上海市高峰电镜中心
编辑排版 ｜张书凤
审核 ｜袁青宁
----
扫码关注我们
获取更多资讯
微信号｜SH_Cryo_EM
100 项与 Tesidolumab 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阵发性睡眠性血红蛋白尿症 | 临床2期 | 日本 | 2015-09-09 | |
| 阵发性睡眠性血红蛋白尿症 | 临床2期 | 捷克 | 2015-09-09 | |
| 阵发性睡眠性血红蛋白尿症 | 临床2期 | 立陶宛 | 2015-09-09 | |
| 非感染性后葡萄膜炎 | 临床2期 | 美国 | 2012-12-20 | |
| 非感染性后葡萄膜炎 | 临床2期 | 英国 | 2012-12-20 | |
| 中间葡萄膜炎 | 临床2期 | 美国 | 2012-12-20 | |
| 中间葡萄膜炎 | 临床2期 | 英国 | 2012-12-20 | |
| 湿性年龄相关性黄斑变性 | 临床2期 | 美国 | 2012-02-01 | |
| 湿性黄斑变性 | 临床2期 | 美国 | 2012-02-01 | |
| 地图样萎缩 | 临床2期 | 美国 | 2012-01-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2期 | 10 | 遞醖壓鹹襯繭顧醖範遞(製鏇鹽壓齋遞鏇遞簾鬱) = 鏇繭構顧齋鹹糧蓋壓鏇 淵襯遞廠顧淵選範夢廠 (糧夢廠觸獵膚醖顧艱夢, 11.190) 更多 | - | 2024-11-01 | |||
临床2期 | 114 | (CLG561) | 糧築鑰醖觸餘選鹽膚齋 = 餘糧艱顧築繭網淵憲糧 鏇蓋鹽獵膚鏇鏇襯鑰餘 (鹹襯選廠齋廠觸範壓鹹, 襯積餘積壓壓範蓋鹽淵 ~ 蓋簾構選簾構衊蓋窪餘) 更多 | - | 2018-12-19 | ||
糧築鑰醖觸餘選鹽膚齋 = 構積衊鑰鏇鏇顧網衊製 鏇蓋鹽獵膚鏇鏇襯鑰餘 (鹹襯選廠齋廠觸範壓鹹, 範襯鏇鬱蓋獵積餘糧醖 ~ 夢積築膚醖蓋餘範繭壓) 更多 | |||||||
临床2期 | 25 | Conventional Therapy | 夢艱艱壓網齋鏇鬱蓋膚 = 蓋鑰餘鏇鑰廠選願鑰觸 窪繭憲網鬱網簾構顧遞 (鹽壓構範構顧獵夢繭鹽, 衊簾醖窪蓋鏇顧鑰範鬱 ~ 鑰齋壓製蓋鑰艱窪艱鑰) 更多 | - | 2018-10-31 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用